a:151:{i:215207;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"APP1";s:12:"field_note_e";s:179:"See Appendix 1 for examples of appropriate dosage preparations and frequencies of use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:12:"field_note_f";s:182:"Consulter l'annexe 1 pour des exemples pertinents de préparations de doses et de fréquences d'emploi, selon les références citées. L'annexe 1 a pour objet de guider l'industrie.";s:16:"field_legacy_nid";s:6:"100550";s:14:"field_workflow";s:9:"Published";s:5:"title";s:184:"APP1_See Appendix 1 for examples of appropriate dosage preparations and frequencies of use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:3:"nid";s:6:"215207";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215208;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"MIN";s:12:"field_note_e";s:155:"The minimum daily doses are based on approximately 5% of the highest AI (IOM 2006). See Appendix 1 for definitions and Table 2 in Appendix 2 for AI values.";s:12:"field_note_f";s:203:"Les doses minimales journalières représentent approximativement 5% de l'AS le plus élevé (IOM 2006). Consulter l'annexe 1 pour les définitions et le tableau 2 de l'annexe 2 pour les valeurs de l'AS.";s:16:"field_legacy_nid";s:6:"100551";s:14:"field_workflow";s:9:"Published";s:5:"title";s:159:"MIN_The minimum daily doses are based on approximately 5% of the highest AI (IOM 2006). See Appendix 1 for definitions and Table 2 in Appendix 2 for AI values.";s:3:"nid";s:6:"215208";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215209;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"MIN2";s:12:"field_note_e";s:157:"The daily minimum doses are based on approximately 5% of the highest RDA (IOM 2006). See Appendix 1 for definitions and Table 3 in Appendix 2 for RDA values.";s:12:"field_note_f";s:207:"Les valeurs minimales journalières représentent approximativement 5% de l'ANR le plus élevé (IOM 2006). Consulter l'annexe 1 pour les définitions et le tableau 3 de l'annexe 2 pour les valeurs de l'ANR.";s:16:"field_legacy_nid";s:6:"100552";s:14:"field_workflow";s:9:"Published";s:5:"title";s:162:"MIN2_The daily minimum doses are based on approximately 5% of the highest RDA (IOM 2006). See Appendix 1 for definitions and Table 3 in Appendix 2 for RDA values.";s:3:"nid";s:6:"215209";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215210;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"MAX99";s:12:"field_note_e";s:88:"The maximum daily doses are supported by the following references: HC 2006 and FSA 2003.";s:12:"field_note_f";s:109:"Les doses maximales journalières ont été établies selon les références suivantes : SC 2006 et FSA 2003.";s:16:"field_legacy_nid";s:6:"100553";s:14:"field_workflow";s:9:"Published";s:5:"title";s:94:"MAX99_The maximum daily doses are supported by the following references: HC 2006 and FSA 2003.";s:3:"nid";s:6:"215210";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215211;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"MAX";s:12:"field_note_e";s:125:"The maximum daily dose is based on the Tolerable Upper Intake Level (UL) less average dietary intake (adapted from IOM 2006).";s:12:"field_note_f";s:146:"La dose maximale journalière est fondée sur l'apport maximal tolérable (AMT) moins l'apport nutritionnel moyen (adaptée du document IOM 2006).";s:16:"field_legacy_nid";s:6:"100554";s:14:"field_workflow";s:9:"Published";s:5:"title";s:129:"MAX_The maximum daily dose is based on the Tolerable Upper Intake Level (UL) less average dietary intake (adapted from IOM 2006).";s:3:"nid";s:6:"215211";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215212;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXCHR";s:12:"field_note_e";s:149:"The maximum daily dose is supported by the following references: Anderson et al. 2001; Crawford et al. 1999; Roeback et al. 1991; Mossop et al. 1983.";s:12:"field_note_f";s:166:"La dose maximale journalière a été établie selon les références suivantes : Anderson et al. 2001; Crawford et al. 1999; Roeback et al. 1991; Mossop et al. 1983.";s:16:"field_legacy_nid";s:6:"100555";s:14:"field_workflow";s:9:"Published";s:5:"title";s:156:"MAXCHR_The maximum daily dose is supported by the following references: Anderson et al. 2001; Crawford et al. 1999; Roeback et al. 1991; Mossop et al. 1983.";s:3:"nid";s:6:"215212";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215213;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"ADUL";s:12:"field_note_e";s:49:"Adults includes pregnant and breastfeeding women.";s:12:"field_note_f";s:71:"La sous-population adulte comprend les femmes enceintes et allaitantes.";s:16:"field_legacy_nid";s:6:"100556";s:14:"field_workflow";s:9:"Published";s:5:"title";s:54:"ADUL_Adults includes pregnant and breastfeeding women.";s:3:"nid";s:6:"215213";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215214;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"FOL";s:12:"field_note_e";s:127:"For products with more than 199 micrograms/day of Folate, please refer to the NHPD multi-vitamin/ mineral supplement monograph.";s:12:"field_note_f";s:181:"Pour des produits qui contiennent plus de 199 microgrammes/jour de Folate, veuillez faire référence à la monographie de la DPSN sur les suppléments de multivitamines/ minéraux.";s:16:"field_legacy_nid";s:6:"100557";s:14:"field_workflow";s:9:"Published";s:5:"title";s:131:"FOL_For products with more than 199 micrograms/day of Folate, please refer to the NHPD multi-vitamin/ mineral supplement monograph.";s:3:"nid";s:6:"215214";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215215;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"IRON";s:12:"field_note_e";s:163:"For products providing a daily dose of iron above 35 mg, per day, the Specific use or purpose and/or the Dose-specific use or purpose indicated above are required.";s:12:"field_note_f";s:200:"L’usage ou fin recommandés spécifique ou ceux qui sont propres à la dose (énumérés ci-dessus) sont requis dans le cas des produits fournissant une dose quotidienne de fer supérieure à 35 mg.";s:16:"field_legacy_nid";s:6:"100558";s:14:"field_workflow";s:9:"Published";s:5:"title";s:168:"IRON_For products providing a daily dose of iron above 35 mg, per day, the Specific use or purpose and/or the Dose-specific use or purpose indicated above are required.";s:3:"nid";s:6:"215215";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215216;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXIRO";s:12:"field_note_e";s:147:"The maximum daily doses are based on the Tolerable Upper Intake Level (UL) which applies to total iron intake from food and supplements (IOM 2006).";s:12:"field_note_f";s:178:"Les doses maximales journalières sont fondées sur l'apport maximal tolérable (AMT) qui représente l'apport total en fer provenant des aliments et des suppléments (IOM 2006).";s:16:"field_legacy_nid";s:6:"100559";s:14:"field_workflow";s:9:"Published";s:5:"title";s:154:"MAXIRO_The maximum daily doses are based on the Tolerable Upper Intake Level (UL) which applies to total iron intake from food and supplements (IOM 2006).";s:3:"nid";s:6:"215216";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215217;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXMAG";s:12:"field_note_e";s:241:"The maximum daily doses for children and adolescents are based on the UL which applies to magnesium intake from supplements only (IOM 2006). Maximum dose for adults supported by the following references: Lopez-Ridaura et al. 2004; Rude 1998.";s:12:"field_note_f";s:309:"Les doses maximales journalières pour enfants et adolescents sont fondées sur l'AMT qui représente l'apport total en magnésium provenant des uniquement des suppléments (IOM 2006). La doses maximale pour les adultes a été établie selon les références suivantes : Lopez-Ridaura et al. 2004; Rude 1998.";s:16:"field_legacy_nid";s:6:"100560";s:14:"field_workflow";s:9:"Published";s:5:"title";s:248:"MAXMAG_The maximum daily doses for children and adolescents are based on the UL which applies to magnesium intake from supplements only (IOM 2006). Maximum dose for adults supported by the following references: Lopez-Ridaura et al. 2004; Rude 1998.";s:3:"nid";s:6:"215217";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215218;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"MAGSPEC";s:12:"field_note_e";s:173:"At least one of the Specific or Dose-specific use or purpose statements indicated above must be given for magnesium products providing more than 350 mg of magnesium per day.";s:12:"field_note_f";s:200:"Au moins un des usages ou fins recommandés spécifiques ou propre à la dose (énumérés ci-dessus) est requis dans le cas des produits fournissant une dose de magnésium supérieure à 350 mg/jour.";s:16:"field_legacy_nid";s:6:"100561";s:14:"field_workflow";s:9:"Published";s:5:"title";s:181:"MAGSPEC_At least one of the Specific or Dose-specific use or purpose statements indicated above must be given for magnesium products providing more than 350 mg of magnesium per day.";s:3:"nid";s:6:"215218";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215219;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXNIA";s:12:"field_note_e";s:287:"The maximum daily doses for children and adolescents are based on the UL which applies to total nicotinic acid and/or niacinamide intake from food and supplements (IOM 2006). Maximum dose for adults supported by the following references: HC 2007, FSA 2003, Mills et al. 2003 and EC 2002.";s:12:"field_note_f";s:344:"Les doses maximales journalières pour enfants et adolescents sont fondées sur l'AMT qui représente l'apport total en acide nicotinique et/ou en niacinamide provenant des aliments et suppléments (IOM 2006). La dose maximale pour les adultes a été établie selon les références suivantes : SC 2007, FSA 2003, Mills et al. 2003 et EC 2002.";s:16:"field_legacy_nid";s:6:"100562";s:14:"field_workflow";s:9:"Published";s:5:"title";s:255:"MAXNIA_The maximum daily doses for children and adolescents are based on the UL which applies to total nicotinic acid and/or niacinamide intake from food and supplements (IOM 2006). Maximum dose for adults supported by the following references: HC 2007...";s:3:"nid";s:6:"215219";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215220;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXPAA";s:12:"field_note_e";s:74:"The maximum daily doses are supported by the following reference: HC 2006.";s:12:"field_note_f";s:94:"Les doses maximales journalières ont été établies selon la référence suivante : SC 2006.";s:16:"field_legacy_nid";s:6:"100563";s:14:"field_workflow";s:9:"Published";s:5:"title";s:81:"MAXPAA_The maximum daily doses are supported by the following reference: HC 2006.";s:3:"nid";s:6:"215220";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215221;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"CONPAA";s:12:"field_note_e";s:562:"Conversion factors (USP 30)  ---  
Table 2: Conversion of pantothenic acid source material quantity into pantothenic acid quantity:      
Source material (1 mg) = Pantothenic acid quantity (mg)  *   
d-Pantothenic acid (1 mg) = 1.00 mg of pantothenic acid   *  
d-Panthenol (1 mg) = 1.07 mg of pantothenic acid   *  
Calcium-d-pantothenate (1 mg) = 0.92 mg of pantothenic acid  *   
dl-Pantothenic acid (1 mg) = 0.50 mg of pantothenic acid   *  
dl-Panthenol (1 mg) = 0.54 mg of pantothenic acid   *  
Calcium-dl-pantothenate (1 mg) = 0.46 mg of pantothenic acid";s:12:"field_note_f";s:664:"Facteurs de conversion (USP 30)   ---   
Tableau 2 : Conversion de la quantité de la matière d’origine de l’acide pantothénique en quantité d’acide pantothénique:  
Matière d’origine (1 mg) = Quantité d’acide pantothénique (mg)   *  
Acide d-pantothénique (1 mg) = 1,00 mg d’acide pantothénique   *  
d-Panthénol (1 mg) = 1,07 mg d’acide pantothénique    *   
d-Pantothénate de calcium (1 mg) = 0,92 mg d’acide pantothénique   *  
Acide dl-pantothénique (1 mg) = 0,50 mg d’acide pantothénique   *  
dl-Panthénol (1 mg) = 0,54 mg d’acide pantothénique   *  
dl-Pantothénate de calcium (1 mg) = 0,46 mg d’acide pantothénique";s:16:"field_legacy_nid";s:6:"100564";s:14:"field_workflow";s:9:"Published";s:5:"title";s:44:"CONPAA_Conversion factors (USP 30)  ---  ...";s:3:"nid";s:6:"215221";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215222;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXRIB";s:12:"field_note_e";s:109:"The maximum daily doses are supported by the following references: HC 2006, Boehnke et al. 2004 and FSA 2003.";s:12:"field_note_f";s:130:"Les doses maximales journalières ont été établies selon les références suivantes : SC 2006, Boehnke et al. 2004 et FSA 2003.";s:16:"field_legacy_nid";s:6:"100565";s:14:"field_workflow";s:9:"Published";s:5:"title";s:116:"MAXRIB_The maximum daily doses are supported by the following references: HC 2006, Boehnke et al. 2004 and FSA 2003.";s:3:"nid";s:6:"215222";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215223;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXSEL";s:12:"field_note_e";s:149:"The maximum daily dose is based on the Tolerable Upper Intake Level (UL) which applies to total selenium intake from food and supplements (IOM 2006).";s:12:"field_note_f";s:183:"La dose maximale journalière est fondée sur l’apport maximal tolérable (AMT) qui représente l’apport total en sélénium provenant des aliments et des suppléments (IOM 2006).";s:16:"field_legacy_nid";s:6:"100566";s:14:"field_workflow";s:9:"Published";s:5:"title";s:156:"MAXSEL_The maximum daily dose is based on the Tolerable Upper Intake Level (UL) which applies to total selenium intake from food and supplements (IOM 2006).";s:3:"nid";s:6:"215223";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215224;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXVB1";s:12:"field_note_e";s:99:"The maximum daily doses are supported by the following references: HC 2006 and Gokhale et al. 1996.";s:12:"field_note_f";s:120:"Les doses maximales journalières ont été établies selon les références suivantes : SC 2006 et Gokhale et al. 1996.";s:16:"field_legacy_nid";s:6:"100567";s:14:"field_workflow";s:9:"Published";s:5:"title";s:106:"MAXVB1_The maximum daily doses are supported by the following references: HC 2006 and Gokhale et al. 1996.";s:3:"nid";s:6:"215224";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215225;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"VIARAE";s:12:"field_note_e";s:94:"Vitamin A must be expressed as micrograms or milligrams of retinol activity equivalents (RAE).";s:12:"field_note_f";s:124:"La quantité de vitamine A doit être exprimée en microgrammes ou milligrammes d'équivalent d'activité du rétinol (EAR).";s:16:"field_legacy_nid";s:6:"100568";s:14:"field_workflow";s:9:"Published";s:5:"title";s:101:"VIARAE_Vitamin A must be expressed as micrograms or milligrams of retinol activity equivalents (RAE).";s:3:"nid";s:6:"215225";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215226;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXVIA";s:12:"field_note_e";s:152:"The maximum daily doses are based on the Tolerable Upper Intake Level (UL) which applies to total vitamin A intake from food and supplements (IOM 2006).";s:12:"field_note_f";s:186:"Les doses maximales journalières sont fondées sur l'apport maximal tolérable (AMT), qui représente l'apport total en vitamine A provenant des aliments et des suppléments (IOM 2006).";s:16:"field_legacy_nid";s:6:"100569";s:14:"field_workflow";s:9:"Published";s:5:"title";s:159:"MAXVIA_The maximum daily doses are based on the Tolerable Upper Intake Level (UL) which applies to total vitamin A intake from food and supplements (IOM 2006).";s:3:"nid";s:6:"215226";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215227;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"VIABET";s:12:"field_note_e";s:272:"As per the NHPD Multi-vitamin/mineral Supplement Monograph, the maximum daily dose for vitamin A in combination with beta-carotene must not exceed the Tolerable Upper Intake Level (UL) for vitamin A. See the Multi-vitamin/mineral Supplement Monograph for more information.";s:12:"field_note_f";s:362:"Selon la monographie des suppléments de multivitamines/minéraux de la DPSN, la dose quotidienne maximale de vitamine A en association avec le bêta-carotène ne doit pas dépasser l'apport maximal tolérable (l'AMT) fixé pour la vitamine A (IOM 2006). Consulter la monographie des suppléments de multivitamines/minéraux pour des renseignements additionnels.";s:16:"field_legacy_nid";s:6:"100570";s:14:"field_workflow";s:9:"Published";s:5:"title";s:250:"VIABET_As per the NHPD Multi-vitamin/mineral Supplement Monograph, the maximum daily dose for vitamin A in combination with beta-carotene must not exceed the Tolerable Upper Intake Level (UL) for vitamin A. See the Multi-vitamin/mineral Supplement...";s:3:"nid";s:6:"215227";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215228;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"CONVIA";s:12:"field_note_e";s:347:"The quantity of vitamin A must always be provided in terms of retinol activity equivalents (RAE) (i.e. micrograms of all-trans retinol), irrespective of the source material used.  International Units (IU) may be provided as optional additional information on the Product Licence Application (PLA) form in the "potency" field and on product labels.";s:12:"field_note_f";s:462:"La quantité de vitamine A doit toujours être exprimée en équivalents d'activité du rétinol (EAR) (i.e. en microgrammes de rétinol tout trans), sans égard à la matière d'origine utilisée.   La mention des unités internationales (UI) peut figurer à titre de renseignement complémentaire facultatif sur le formulaire de demande de licence de mise en marché (DLMM), dans le champ indiquant « l'activité » du produit, et sur l'étiquette du produit.";s:16:"field_legacy_nid";s:6:"100571";s:14:"field_workflow";s:9:"Published";s:5:"title";s:253:"CONVIA_The quantity of vitamin A must always be provided in terms of retinol activity equivalents (RAE) (i.e. micrograms of all-trans retinol), irrespective of the source material used.  International Units (IU) may be provided as optional additional...";s:3:"nid";s:6:"215228";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215229;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"CONVIA2";s:12:"field_note_e";s:431:"Conversion Factors:   (i) All-trans retinol (1 microgram) =  1.00 Vitamin A (microgram RAE) = 3.33 Vitamin A activity (IU); (ii)  All-trans retinyl acetate (1 microgram) = 0.87 Vitamin A (microgram RAE) =  2.94 Vitamin A activity (IU); (iii)  All-trans retinyl palmitate (1 microgram) = 0.55 Vitamin A (microgram RAE) =  1.82 Vitamin A activity (IU).  See Appendix 3 for examples on how to use the conversion factors appropriately.";s:12:"field_note_f";s:499:"Facteurs de conversion :    (i) Acétate de rétinyle tout trans (1 microgramme) =  0,87 Vitamine A (microgramme EAR) = 2,94 Activité de la vitamine A (UI); (ii) Palmitate de rétinyle tout trans (1 microgramme) = 0,55 Vitamine A (microgramme EAR) = 1,82 Activité de la vitamine A (UI); (iii) Rétinol tout trans (1 microgramme) = 1,00 Vitamine A (microgramme EAR) = 3,33 Activité de la vitamine A (UI). Consulter l'annexe 3 pour des exemples d'utilisation appropriée des facteurs de conversion.";s:16:"field_legacy_nid";s:6:"100572";s:14:"field_workflow";s:9:"Published";s:5:"title";s:253:"CONVIA2_Conversion Factors:   (i) All-trans retinol (1 microgram) =  1.00 Vitamin A (microgram RAE) = 3.33 Vitamin A activity (IU); (ii)  All-trans retinyl acetate (1 microgram) = 0.87 Vitamin A (microgram RAE) =  2.94 Vitamin A activity (IU); (iii) ...";s:3:"nid";s:6:"215229";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215230;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXVB6";s:12:"field_note_e";s:154:"The maximum daily doses are based on the Tolerable Upper Intake Level (UL), which applies to total vitamin B6 intake from food and supplements (IOM 2006).";s:12:"field_note_f";s:187:"Les doses maximales journalières sont fondées sur l'apport maximal tolérable (AMT), qui représente l'apport total en vitamine B6 provenant des aliments et des suppléments (IOM 2006).";s:16:"field_legacy_nid";s:6:"100573";s:14:"field_workflow";s:9:"Published";s:5:"title";s:161:"MAXVB6_The maximum daily doses are based on the Tolerable Upper Intake Level (UL), which applies to total vitamin B6 intake from food and supplements (IOM 2006).";s:3:"nid";s:6:"215230";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215231;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXVIC";s:12:"field_note_e";s:152:"The maximum daily doses are based on the Tolerable Upper Intake Level (UL) which applies to total vitamin C intake from food and supplements (IOM 2006).";s:12:"field_note_f";s:185:"Les doses maximales journalières sont fondées sur l'apport maximal tolérable (AMT) qui représente l'apport total en vitamine C provenant des aliments et des suppléments (IOM 2006).";s:16:"field_legacy_nid";s:6:"100574";s:14:"field_workflow";s:9:"Published";s:5:"title";s:159:"MAXVIC_The maximum daily doses are based on the Tolerable Upper Intake Level (UL) which applies to total vitamin C intake from food and supplements (IOM 2006).";s:3:"nid";s:6:"215231";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215232;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXVID";s:12:"field_note_e";s:93:"The maximum daily value is based on the Food and Drug Regulations Schedule F limit (HC 2007).";s:12:"field_note_f";s:134:"La dose maximale journalière est basée sur la limite établie dans l’annexe F du Règlement sur les aliments et drogues (SC 2007).";s:16:"field_legacy_nid";s:6:"100575";s:14:"field_workflow";s:9:"Published";s:5:"title";s:100:"MAXVID_The maximum daily value is based on the Food and Drug Regulations Schedule F limit (HC 2007).";s:3:"nid";s:6:"215232";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215233;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"CONVID";s:12:"field_note_e";s:171:"Conversion Factors:   1 IU of vitamin D activity    =  0.025 microgram cholecalciferol (IOM 2006);  and,     1 IU of vitamin D activity   =  0.025 microgram ergocalciferol";s:12:"field_note_f";s:192:"Facteurs de conversion:   1 UI d'activité de vitamine D   =  0,025 microgramme de cholécalciférol (IOM 2006); et,    1 UI d'activité de vitamine D    =  0,025 microgramme d'ergocalciférol";s:16:"field_legacy_nid";s:6:"100576";s:14:"field_workflow";s:9:"Published";s:5:"title";s:178:"CONVID_Conversion Factors:   1 IU of vitamin D activity    =  0.025 microgram cholecalciferol (IOM 2006);  and,     1 IU of vitamin D activity   =  0.025 microgram ergocalciferol";s:3:"nid";s:6:"215233";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215234;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXZNC";s:12:"field_note_e";s:301:"The maximum daily doses for children and adolescents are based on the UL which applies to total zinc intake from food and supplements (IOM 2006). Maximum dose for adults supported by the following references: HC 2007b, Milne et al. 2001, Davis et al. 2000, Yadrick et al. 1989 and Fischer et al. 1984.";s:12:"field_note_f";s:358:"Les doses maximales journalières pour enfants et adolescents sont fondées sur l'AMT qui représente l'apport total en zinc provenant des aliments et des suppléments (IOM 2006). La doses maximale pour les adultes a été établie selon les références suivantes : SC 2007b, Milne et al. 2001, Davis et al. 2000, Yadrick et al. 1989 et Fischer et al. 1984.";s:16:"field_legacy_nid";s:6:"100577";s:14:"field_workflow";s:9:"Published";s:5:"title";s:253:"MAXZNC_The maximum daily doses for children and adolescents are based on the UL which applies to total zinc intake from food and supplements (IOM 2006). Maximum dose for adults supported by the following references: HC 2007b, Milne et al. 2001, Davis...";s:3:"nid";s:6:"215234";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215235;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"ZNCCOP";s:12:"field_note_e";s:386:"Products providing zinc without copper or with copper at doses less than those specified below must be labelled with the risk statement in the Known Adverse Reaction section below.     
[ Life Stage Group   ///   Zinc (doses exceeding UL - average Intake) (mg/day)    ///   Required Copper (Zn:Cu 25:1) (µg/day) ] 
[ Infants 0-12 mo   ///    = 19 y    ///   31-50   ///   2,000-8,000 ]";s:12:"field_note_f";s:470:"Les produits fournissant des doses de zinc sans cuivre ou à des doses de cuivre inférieures à celles énoncées ci-dessus doivent avoir sur leur étiquette la mention de risque présenté à la section des réactions indésirables connues retrouvée ci-dessus.     
[ Groupe d'âges selon l'étape de vie    ///     Zinc (doses supérieures à l'AMT - apport moyen) (mg/jour)     ///    Cuivre requis (Zn:Cu 25:1) (µg/jour) ]   
[ Nourrissons de 0 à 12 mois     ///";s:16:"field_legacy_nid";s:6:"100578";s:14:"field_workflow";s:9:"Published";s:5:"title";s:195:"ZNCCOP_Products providing zinc without copper or with copper at doses less than those specified below must be labelled with the risk statement in the Known Adverse Reaction section below.     ...";s:3:"nid";s:6:"215235";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215236;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"ZNCSPEC";s:12:"field_note_e";s:162:"At least one of the Specific or Dose-specific use or purpose statements indicated above must be given for zinc products providing more than 40 mg of zinc per day.";s:12:"field_note_f";s:193:"Au moins un des usages ou fins recommandés spécifiques ou propre à la dose (énumérés ci-dessus) est requis dans le cas des produits fournissant une dose de zinc supérieure à 40 mg/jour.";s:16:"field_legacy_nid";s:6:"100579";s:14:"field_workflow";s:9:"Published";s:5:"title";s:170:"ZNCSPEC_At least one of the Specific or Dose-specific use or purpose statements indicated above must be given for zinc products providing more than 40 mg of zinc per day.";s:3:"nid";s:6:"215236";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215237;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXBET";s:12:"field_note_e";s:165:"The maximum daily dose is based on the Tolerable Upper Intake Level (UL) for vitamin A, which applies to total vitamin A intake from food and supplements (IOM 2006).";s:12:"field_note_f";s:203:"La dose maximale journalière est fondée sur l’apport maximal tolérable (AMT) pour la vitamine A, qui représente l’apport total en vitamine A provenant des aliments et des suppléments (IOM 2006).";s:16:"field_legacy_nid";s:6:"100580";s:14:"field_workflow";s:9:"Published";s:5:"title";s:172:"MAXBET_The maximum daily dose is based on the Tolerable Upper Intake Level (UL) for vitamin A, which applies to total vitamin A intake from food and supplements (IOM 2006).";s:3:"nid";s:6:"215237";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215238;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"MAXBCVA";s:12:"field_note_e";s:295:"As per the NHPD Multi-vitamin/mineral Supplement Monograph, the maximum daily dose for beta-carotene in combination with other vitamin A source materials must not exceed the Tolerable Upper Intake Level (UL) for vitamin A. See the Multi-vitamin/mineral Supplement Monograph for more information.";s:12:"field_note_f";s:391:"Selon la monographie des suppléments de multivitamines/minéraux de la DPSN, la dose quotidienne maximale de bêta-carotène en association avec d'autres matières d'origine de vitamine A ne doit pas dépasser l'apport maximal tolérable (l'AMT) fixé pour la vitamine A (IOM 2006). Consulter la monographie des suppléments de multivitamines/minéraux pour des renseignements additionnels.";s:16:"field_legacy_nid";s:6:"100581";s:14:"field_workflow";s:9:"Published";s:5:"title";s:255:"MAXBCVA_As per the NHPD Multi-vitamin/mineral Supplement Monograph, the maximum daily dose for beta-carotene in combination with other vitamin A source materials must not exceed the Tolerable Upper Intake Level (UL) for vitamin A. See the Multi-vitamin...";s:3:"nid";s:6:"215238";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215239;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"CONBET";s:12:"field_note_e";s:197:"International Units (IU) may be provided as optional additional information on the PLA form, using the following USP conversion factor:   1 IU of beta-carotene = 0.6 µg of all-trans beta-carotene.";s:12:"field_note_f";s:240:"La mention des unités internationales (UI) peut figurer à titre de renseignement additionnel facultatif sur la DLMM, en utilisant le facteur de conversion « USP » suivant : 1 UI de bêta-carotène = 0,6 µg de beta-carotène tout trans.";s:16:"field_legacy_nid";s:6:"100582";s:14:"field_workflow";s:9:"Published";s:5:"title";s:204:"CONBET_International Units (IU) may be provided as optional additional information on the PLA form, using the following USP conversion factor:   1 IU of beta-carotene = 0.6 µg of all-trans beta-carotene.";s:3:"nid";s:6:"215239";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215240;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"FRAD";s:12:"field_note_e";s:90:"Children and adolescent doses were calculated as a proportion of the adult dose (JC 2012).";s:12:"field_note_f";s:120:"Les doses pour les enfants et les adolescents ont été calculées à partir d'une fraction de la dose adulte (JC 2012).";s:16:"field_legacy_nid";s:6:"100583";s:14:"field_workflow";s:9:"Published";s:5:"title";s:95:"FRAD_Children and adolescent doses were calculated as a proportion of the adult dose (JC 2012).";s:3:"nid";s:6:"215240";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215241;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"LIN1";s:12:"field_note_e";s:129:"The use of linden in children and adolescents is supported by the following references: McIntyre 2005; Schilcher 1997; Bove 1996.";s:12:"field_note_f";s:135:"Les références suivantes appuient l'emploi du tilleul chez les enfants et les adolescents : McIntyre 2005; Schilcher 1997; Bove 1996.";s:16:"field_legacy_nid";s:6:"100584";s:14:"field_workflow";s:9:"Published";s:5:"title";s:134:"LIN1_The use of linden in children and adolescents is supported by the following references: McIntyre 2005; Schilcher 1997; Bove 1996.";s:3:"nid";s:6:"215241";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215242;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"LIN2";s:12:"field_note_e";s:131:"Adult dose supported by the following references: Hoffmann 2003; Blumenthal et al. 2000; Bradley 1992; Felter and Lloyd 1983[1898].";s:12:"field_note_f";s:156:"Les références suivantes ont servi à établir la dose pour les adultes : Hoffmann 2003; Blumenthal et al. 2000; Bradley 1992; Felter et Lloyd 1983[1898].";s:16:"field_legacy_nid";s:6:"100585";s:14:"field_workflow";s:9:"Published";s:5:"title";s:136:"LIN2_Adult dose supported by the following references: Hoffmann 2003; Blumenthal et al. 2000; Bradley 1992; Felter and Lloyd 1983[1898].";s:3:"nid";s:6:"215242";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215243;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"ADAD";s:12:"field_note_e";s:63:"Adolescents and adults include pregnant and breastfeeding women";s:12:"field_note_f";s:75:"Les adolescents et adultes comprennent les femmes enceintes et allaitantes.";s:16:"field_legacy_nid";s:6:"100586";s:14:"field_workflow";s:9:"Published";s:5:"title";s:68:"ADAD_Adolescents and adults include pregnant and breastfeeding women";s:3:"nid";s:6:"215243";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215244;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"LIC1";s:12:"field_note_e";s:131:"The use of licorice in children and adolescents is supported by the following references: McIntyre 2005; Schilcher 1997; Bove 1996.";s:12:"field_note_f";s:142:"Les références suivantes appuient l’emploi de la réglisse chez les enfants et les adolescents : McIntyre 2005; Schilcher 1997; Bove 1996.";s:16:"field_legacy_nid";s:6:"100587";s:14:"field_workflow";s:9:"Published";s:5:"title";s:136:"LIC1_The use of licorice in children and adolescents is supported by the following references: McIntyre 2005; Schilcher 1997; Bove 1996.";s:3:"nid";s:6:"215244";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215245;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"LIC2";s:12:"field_note_e";s:135:"Adult dose supported by the following references: Mills and Bone 2005; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000; Bradley 1992.";s:12:"field_note_f";s:160:"Les références suivantes ont servi à établir la dose pour les adultes : Mills et Bone 2005; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000; Bradley 1992.";s:16:"field_legacy_nid";s:6:"100588";s:14:"field_workflow";s:9:"Published";s:5:"title";s:140:"LIC2_Adult dose supported by the following references: Mills and Bone 2005; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000; Bradley 1992.";s:3:"nid";s:6:"215245";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215246;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"PEP1";s:12:"field_note_e";s:122:"The use of peppermint leaf in children and adolescents is supported by the following references: McIntyre 2005; Bove 1996.";s:12:"field_note_f";s:132:"Les références suivantes appuient l’emploi de la menthe poivrée chez les enfants et les adolescents : McIntyre 2005; Bove 1996.";s:16:"field_legacy_nid";s:6:"100589";s:14:"field_workflow";s:9:"Published";s:5:"title";s:127:"PEP1_The use of peppermint leaf in children and adolescents is supported by the following references: McIntyre 2005; Bove 1996.";s:3:"nid";s:6:"215246";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215247;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"PEP2";s:12:"field_note_e";s:120:"Adult dose supported by the following references: Mills and Bone 2005; ESCOP 2003; Blumenthal et al. 2000; Bradley 1992.";s:12:"field_note_f";s:160:"Les références suivantes ont servi à établir la dose pour les adultes : Mills et Bone 2005; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000; Bradley 1992.";s:16:"field_legacy_nid";s:6:"100590";s:14:"field_workflow";s:9:"Published";s:5:"title";s:125:"PEP2_Adult dose supported by the following references: Mills and Bone 2005; ESCOP 2003; Blumenthal et al. 2000; Bradley 1992.";s:3:"nid";s:6:"215247";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215248;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"PEP3";s:12:"field_note_e";s:132:"The use of peppermint distilled oil in children and adolescents is supported by the following references:  McIntyre 2005; Bove 1996.";s:12:"field_note_f";s:156:"Les références suivantes appuient l’emploi de l’huile distillée de la menthe poivrée chez les enfants et les adolescents : McIntyre 2005; Bove 1996.";s:16:"field_legacy_nid";s:6:"100591";s:14:"field_workflow";s:9:"Published";s:5:"title";s:137:"PEP3_The use of peppermint distilled oil in children and adolescents is supported by the following references:  McIntyre 2005; Bove 1996.";s:3:"nid";s:6:"215248";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215249;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"ARN1";s:12:"field_note_e";s:101:"Applicants are not required to disclose a quantity of crude equivalent (QCE) for arnica preparations.";s:12:"field_note_f";s:125:"Le demandeur n'est pas dans l'obligation de soumettre une quantité brute équivalente (QBE) pour les préparations d'arnica.";s:16:"field_legacy_nid";s:6:"100592";s:14:"field_workflow";s:9:"Published";s:5:"title";s:106:"ARN1_Applicants are not required to disclose a quantity of crude equivalent (QCE) for arnica preparations.";s:3:"nid";s:6:"215249";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215250;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"ARN2";s:12:"field_note_e";s:133:"Extraction ratios are required on the Product Licence Application and product label for tinctures and ointments containing tinctures.";s:12:"field_note_f";s:180:"Pour les teintures et les onguents contenant des teintures, les ratios d'extraction doivent apparaître sur la demande de licence de mise en marché et sur l'étiquette du produit.";s:16:"field_legacy_nid";s:6:"100593";s:14:"field_workflow";s:9:"Published";s:5:"title";s:138:"ARN2_Extraction ratios are required on the Product Licence Application and product label for tinctures and ointments containing tinctures.";s:3:"nid";s:6:"215250";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215251;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"ARN3";s:12:"field_note_e";s:208:"For tinctures and ointments, see Appendix 1 for examples of appropriate dosage preparations and directions for use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:12:"field_note_f";s:212:"Pour les teintures et les onguents, consulter l'annexe 1 pour des exemples pertinents de préparations de doses et de modes d'emploi, selon les références citées. L'annexe 1 a pour objet de guider l'industrie.";s:16:"field_legacy_nid";s:6:"100594";s:14:"field_workflow";s:9:"Published";s:5:"title";s:213:"ARN3_For tinctures and ointments, see Appendix 1 for examples of appropriate dosage preparations and directions for use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:3:"nid";s:6:"215251";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215252;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"EPE";s:12:"field_note_e";s:138:"In view of the toxicity of European pennyroyal oil (Barnes et al. 2007), alcoholic extracts with a ratio other than 1:1 are not permitted.";s:12:"field_note_f";s:168:"Étant donné la toxicité de l'huile de la menthe pouliot (Barnes et al. 2007), les extraits alcooliques ayant un ratio d'extraction autre que 1:1 ne  sont pas permis.";s:16:"field_legacy_nid";s:6:"100595";s:14:"field_workflow";s:9:"Published";s:5:"title";s:142:"EPE_In view of the toxicity of European pennyroyal oil (Barnes et al. 2007), alcoholic extracts with a ratio other than 1:1 are not permitted.";s:3:"nid";s:6:"215252";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215253;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"ECH1";s:12:"field_note_e";s:129:"The use of Echinacea angustifolia in children is supported by the following references: McIntyre 2005; Bove 2001; Schilcher 1997.";s:12:"field_note_f";s:135:"Les références suivantes appuient l'emploi de l'échinacée angustifolia chez les enfants : McIntyre 2005; Bove 2001; Schilcher 1997.";s:16:"field_legacy_nid";s:6:"100596";s:14:"field_workflow";s:9:"Published";s:5:"title";s:134:"ECH1_The use of Echinacea angustifolia in children is supported by the following references: McIntyre 2005; Bove 2001; Schilcher 1997.";s:3:"nid";s:6:"215253";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215254;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"ECH2";s:12:"field_note_e";s:106:"Adult dose supported by the following references: Barnes et al. 2007; Blumenthal et al. 2000; Bradley 1992";s:12:"field_note_f";s:132:"Les références suivantes ont servi à établir la dose pour les adultes : Barnes et al. 2007; Blumenthal et al. 2000; Bradley 1992";s:16:"field_legacy_nid";s:6:"100597";s:14:"field_workflow";s:9:"Published";s:5:"title";s:111:"ECH2_Adult dose supported by the following references: Barnes et al. 2007; Blumenthal et al. 2000; Bradley 1992";s:3:"nid";s:6:"215254";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215255;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"GARCH";s:12:"field_note_e";s:113:"The use of garlic in children is supported by the following references: McIntyre 2005; Schilcher 1997; Bove 2001.";s:12:"field_note_f";s:114:"Les références suivantes appuient l'emploi de l'ail chez les enfants : McIntyre 2005; Schilcher 1997; Bove 2001.";s:16:"field_legacy_nid";s:6:"100598";s:14:"field_workflow";s:9:"Published";s:5:"title";s:119:"GARCH_The use of garlic in children is supported by the following references: McIntyre 2005; Schilcher 1997; Bove 2001.";s:3:"nid";s:6:"215255";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215256;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"GARADU";s:12:"field_note_e";s:160:"Adult dose supported by the following references: Kojuri et al. 2006; Mills and Bone 2005; ESCOP 2003; Kannar et al. 2001; Blumenthal et al. 2000; Bradley 1992.";s:12:"field_note_f";s:185:"Les références suivantes ont servi à établir la dose pour les adultes : Kojuri et al. 2006; Mills et Bone 2005; ESCOP 2003; Kannar et al. 2001; Blumenthal et al. 2000; Bradley 1992.";s:16:"field_legacy_nid";s:6:"100599";s:14:"field_workflow";s:9:"Published";s:5:"title";s:167:"GARADU_Adult dose supported by the following references: Kojuri et al. 2006; Mills and Bone 2005; ESCOP 2003; Kannar et al. 2001; Blumenthal et al. 2000; Bradley 1992.";s:3:"nid";s:6:"215256";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215257;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"ADBR";s:12:"field_note_e";s:50:"Adolescents and adults include breastfeeding women";s:12:"field_note_f";s:62:"Les adolescents et adultes comprennent les femmes allaitantes.";s:16:"field_legacy_nid";s:6:"100600";s:14:"field_workflow";s:9:"Published";s:5:"title";s:55:"ADBR_Adolescents and adults include breastfeeding women";s:3:"nid";s:6:"215257";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215258;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"CINIIN";s:12:"field_note_e";s:257:"Adult dose for allicin supported by the following references: Kojuri et al. 2006; Mills and Bone 2005; ESCOP 2003; Kannar et al. 2001; Bradley 1992. Adult dose for alliin calculated based on the conversion ratio of 0.45 mg allicin: 1 mg alliin (ESCOP 2003).";s:12:"field_note_f";s:308:"Les références suivantes ont servi à établir la dose d'allicine pour les adultes : Kojuri et al. 2006; Mills et Bone 2005; ESCOP 2003; Kannar et al. 2001; Bradley 1992. La dose d'alliine pour adulte a été calculée à partir du taux de conversion suivant : 0,45 mg allicine : 1 mg alliine (ESCOP 2003).";s:16:"field_legacy_nid";s:6:"100601";s:14:"field_workflow";s:9:"Published";s:5:"title";s:254:"CINIIN_Adult dose for allicin supported by the following references: Kojuri et al. 2006; Mills and Bone 2005; ESCOP 2003; Kannar et al. 2001; Bradley 1992. Adult dose for alliin calculated based on the conversion ratio of 0.45 mg allicin: 1 mg alliin ...";s:3:"nid";s:6:"215258";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215259;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"EPA1";s:12:"field_note_e";s:109:"The use of Echinacea pallida in children is supported by the following references: Bove 2001; Schilcher 1997.";s:12:"field_note_f";s:119:"Les références suivantes appuient l’emploi de l’échinacée pallida chez les enfants : Bove 2001; Schilcher 1997.";s:16:"field_legacy_nid";s:6:"100602";s:14:"field_workflow";s:9:"Published";s:5:"title";s:114:"EPA1_The use of Echinacea pallida in children is supported by the following references: Bove 2001; Schilcher 1997.";s:3:"nid";s:6:"215259";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215260;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"EPA2";s:12:"field_note_e";s:144:"Adult dose supported by the following references: EMEA 2009;  Blumenthal 2003; Blumenthal et al. 2000; Blumenthal et al. 1998; Dorn et al. 1997.";s:12:"field_note_f";s:169:"Les références suivantes ont servi à établir la dose pour les adultes : EMEA 2009; Blumenthal 2003; Blumenthal et al. 2000; Blumenthal et al. 1998; Dorn et al. 1997.";s:16:"field_legacy_nid";s:6:"100603";s:14:"field_workflow";s:9:"Published";s:5:"title";s:149:"EPA2_Adult dose supported by the following references: EMEA 2009;  Blumenthal 2003; Blumenthal et al. 2000; Blumenthal et al. 1998; Dorn et al. 1997.";s:3:"nid";s:6:"215260";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215261;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"EPU1";s:12:"field_note_e";s:124:"The use of Echinacea purpurea in children is supported by the following references: McIntyre 2005; Bove 2001; Schilcher 1997";s:12:"field_note_f";s:135:"Les références suivantes appuient l’emploi de l’échinacée purpurea chez les enfants : McIntyre 2005; Bove 2001; Schilcher 1997.";s:16:"field_legacy_nid";s:6:"100604";s:14:"field_workflow";s:9:"Published";s:5:"title";s:129:"EPU1_The use of Echinacea purpurea in children is supported by the following references: McIntyre 2005; Bove 2001; Schilcher 1997";s:3:"nid";s:6:"215261";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215262;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"EPU2";s:12:"field_note_e";s:268:"The following references support adult doses:  (i) herb tops - Mills and Bone 2000, (ii) juice from herb tops - Schulten et al. 2001; Hoheisel et al. 1997,  (iii) root - Mills and Bone 2000; Braunig et al. 1992,  and (iv) both herb tops and root - Mills and Bone 2000.";s:12:"field_note_f";s:310:"Les références suivantes servent à établir les doses pour les adultes:  (i) sommités - Mills et Bone 2000,  (ii) jus de sommités - Schulten et collab 2001; Hoheisel et collab 1997,  (iii) racines - Mills et Bone 2000; Braunig et collab 1992, et  (iv) à la fois sommités et racines - Mills et Bone 2000.";s:16:"field_legacy_nid";s:6:"100605";s:14:"field_workflow";s:9:"Published";s:5:"title";s:255:"EPU2_The following references support adult doses:  (i) herb tops - Mills and Bone 2000, (ii) juice from herb tops - Schulten et al. 2001; Hoheisel et al. 1997,  (iii) root - Mills and Bone 2000; Braunig et al. 1992,  and (iv) both herb tops and root -...";s:3:"nid";s:6:"215262";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215263;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"CREA";s:12:"field_note_e";s:141:"Note: Product licence applicants must include both a loading and maintenance phase dose on the Product Licence Application and product label.";s:12:"field_note_f";s:237:"Nota : Le demandeur de licence de mise en marché doit faire figurer une dose destinée à la phase d'induction et une autre destinée à la phase d'entretien dans la demande de licence de mise en marché et dans l'étiquette du produit.";s:16:"field_legacy_nid";s:6:"100606";s:14:"field_workflow";s:9:"Published";s:5:"title";s:146:"CREA_Note: Product licence applicants must include both a loading and maintenance phase dose on the Product Licence Application and product label.";s:3:"nid";s:6:"215263";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215264;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"FOIL";s:12:"field_note_e";s:129:"Potency must be expressed as the quantity (mg) and/or percent (%) EPA and DHA (% w/w) relative to the total quantity of fish oil.";s:12:"field_note_f";s:169:"L’activité doit être exprimée en quantité (mg) et/ou en pourcentage (%) d’AEP et d’ADH (% poids/poids) par rapport à la quantité totale d’huile de poisson.";s:16:"field_legacy_nid";s:6:"100607";s:14:"field_workflow";s:9:"Published";s:5:"title";s:134:"FOIL_Potency must be expressed as the quantity (mg) and/or percent (%) EPA and DHA (% w/w) relative to the total quantity of fish oil.";s:3:"nid";s:6:"215264";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215265;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"FOIL1";s:12:"field_note_e";s:175:"Adult maximum dose supported by US FDA 1997. Children and adolescent maximum doses, calculated as a fraction of the adult dose, are relative to body weight and caloric intake.";s:12:"field_note_f";s:238:"La référence suivante a servi à établir la dose maximale adulte : FDA 1997. Les doses maximales pour enfants et adolescents, calculées à partir d'une fraction de la dose adulte, dépendent du poids corporel et de l'apport calorique.";s:16:"field_legacy_nid";s:6:"100608";s:14:"field_workflow";s:9:"Published";s:5:"title";s:181:"FOIL1_Adult maximum dose supported by US FDA 1997. Children and adolescent maximum doses, calculated as a fraction of the adult dose, are relative to body weight and caloric intake.";s:3:"nid";s:6:"215265";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215266;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"SOIL";s:12:"field_note_e";s:137:"Potency must be expressed as the quantity (mg) and/or percent (%) of EPA, DHA and DPA (% w/w) relative to the total quantity of seal oil.";s:12:"field_note_f";s:177:"L’activité doit être exprimée en quantité (mg) et/ou en pourcentage (%) d’AEP, d’ADH et d’ADP (% poids/poids) par rapport à la quantité totale d’huile de phoque.";s:16:"field_legacy_nid";s:6:"100609";s:14:"field_workflow";s:9:"Published";s:5:"title";s:142:"SOIL_Potency must be expressed as the quantity (mg) and/or percent (%) of EPA, DHA and DPA (% w/w) relative to the total quantity of seal oil.";s:3:"nid";s:6:"215266";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215267;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"PSYSED";s:12:"field_note_e";s:292:"For psyllium seed, the maximum single dose (13 g) for adults and adolescents (equal or greater than 13 y) is based on the consensus of evidence from several references. The maximum single dose (8 g) for children and adolescents (6-12 y) was calculated as a fraction of the maximum adult doses";s:12:"field_note_f";s:334:"Pour la graine de psyllium,plusieurs références ont servi à établir une limite maximale de 13 g par dose pour les adultes et les adolescents âgées de 13 ans et plus. Une limite maximale de 8 g par dose pour les enfants et les adolescents âgés de 6 à 12 ans a été calculée à partir d’une fraction des doses pour adultes.";s:16:"field_legacy_nid";s:6:"100610";s:14:"field_workflow";s:9:"Published";s:5:"title";s:250:"PSYSED_For psyllium seed, the maximum single dose (13 g) for adults and adolescents (equal or greater than 13 y) is based on the consensus of evidence from several references. The maximum single dose (8 g) for children and adolescents (6-12 y) was...";s:3:"nid";s:6:"215267";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215268;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"PSYHSK";s:12:"field_note_e";s:292:"For psyllium husk, the maximum single dose (8 g) for adults and adolescents (equal or greater than 13 y) is based on the consensus of evidence from several references. The maximum single dose (4 g) for children and adolescents (6-12 y) was calculated as a fraction of the maximum adult doses.";s:12:"field_note_f";s:348:"Pour l'enveloppe de la graine de psyllium, plusieurs références ont servi à établir une limite maximale de 8 g par dose pour les adultes et les adolescents âgés de 13 ans et plus. Une limite maximale de 4 g par dose pour les enfants et les adolescents âgés de 6 à 12 ans a été calculée à partir d’une fraction des doses pour adultes.";s:16:"field_legacy_nid";s:6:"100611";s:14:"field_workflow";s:9:"Published";s:5:"title";s:249:"PSYHSK_For psyllium husk, the maximum single dose (8 g) for adults and adolescents (equal or greater than 13 y) is based on the consensus of evidence from several references. The maximum single dose (4 g) for children and adolescents (6-12 y) was...";s:3:"nid";s:6:"215268";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215269;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"SJW";s:12:"field_note_e";s:143:"Product licence applicants are not required to disclose any extract information (e.g. ratio, method) for topical St. John’s wort preparations";s:12:"field_note_f";s:191:"Les demandeurs de licence de mise en marché ne sont tenus de divulguer les renseignements (e.g. ratios, méthodes) sur les extraits utilisés dans les préparations topiques de millepertuis.";s:16:"field_legacy_nid";s:6:"100612";s:14:"field_workflow";s:9:"Published";s:5:"title";s:147:"SJW_Product licence applicants are not required to disclose any extract information (e.g. ratio, method) for topical St. John’s wort preparations";s:3:"nid";s:6:"215269";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215270;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"HWA";s:12:"field_note_e";s:298:"Witch hazel/Hamamelis water must be the unaltered product resulting from the preparation outlined in the Witch hazel Monograph published in the US Pharmacopoeia.   The term “Witch hazel water” or “Hamamelis water” must appear on the label of products containing Witch hazel/Hamamelis water.";s:12:"field_note_f";s:436:"L’eau d’hamamélis, préparée selon la méthode élaborée dans la monographie Witch Hazel de la pharmacopée américaine (USP), est la seule préparation acceptable pour les produits d’eau d’hamamélis ou contenant de l’eau d’hamamélis; l’eau d’hamamélis ne doit être modifiée en aucun cas.   Le terme « eau d’hamamélis » doit se retrouver sur les étiquettes des produits contenant de l’eau d’hamamélis.";s:16:"field_legacy_nid";s:6:"100613";s:14:"field_workflow";s:9:"Published";s:5:"title";s:256:"HWA_Witch hazel/Hamamelis water must be the unaltered product resulting from the preparation outlined in the Witch hazel Monograph published in the US Pharmacopoeia.   The term “Witch hazel water” or “Hamamelis water” must appear on the label of...";s:3:"nid";s:6:"215270";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215271;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"SSPR";s:12:"field_note_e";s:70:"Semi-solid preparations include ointments, creams, gels and/or salves.";s:12:"field_note_f";s:93:"Les préparations semi-solides incluent les onguents, les crèmes, les gels et/ou les baumes.";s:16:"field_legacy_nid";s:6:"100614";s:14:"field_workflow";s:9:"Published";s:5:"title";s:75:"SSPR_Semi-solid preparations include ointments, creams, gels and/or salves.";s:3:"nid";s:6:"215271";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215272;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"FRA";s:12:"field_note_e";s:104:"Traditional literature suggests frying the resin prior to consumption (Lu 1999; Bensky and Gamble 1986).";s:12:"field_note_f";s:121:"Dans les textes traditionnels, on suggère de faire frire la gomme avant de s'en servir (Lu 1999; Bensky et Gamble 1986).";s:16:"field_legacy_nid";s:6:"100615";s:14:"field_workflow";s:9:"Published";s:5:"title";s:108:"FRA_Traditional literature suggests frying the resin prior to consumption (Lu 1999; Bensky and Gamble 1986).";s:3:"nid";s:6:"215272";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215273;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"MEL";s:12:"field_note_e";s:187:"See Appendix 1 for examples of dosage preparations, frequencies of use and directions for use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:12:"field_note_f";s:193:"Consulter l’annexe 1 pour des exemples de préparations posologiques, de fréquences et de modes d’emploi selon les références citées.  L’annexe 1 a pour objet de guider l’industrie.";s:16:"field_legacy_nid";s:6:"100616";s:14:"field_workflow";s:9:"Published";s:5:"title";s:191:"MEL_See Appendix 1 for examples of dosage preparations, frequencies of use and directions for use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:3:"nid";s:6:"215273";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215274;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"NIA";s:12:"field_note_e";s:166:"For products providing a daily dose of Niacin above 35 mg/day, at least one of the Specific and/or the Dose-specific Use(s) or Purpose(s) indicated above is required.";s:12:"field_note_f";s:208:"Au moins un des usages ou fins recommandés spécifiques et/ou propre à la dose énumérés ci-dessus est requis dans le cas des produits fournissant une dose quotidienne de Niacine supérieure à 35 mg/jour";s:16:"field_legacy_nid";s:6:"100617";s:14:"field_workflow";s:9:"Published";s:5:"title";s:170:"NIA_For products providing a daily dose of Niacin above 35 mg/day, at least one of the Specific and/or the Dose-specific Use(s) or Purpose(s) indicated above is required.";s:3:"nid";s:6:"215274";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215275;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"NIA2";s:12:"field_note_e";s:171:"For products providing a daily dose of Niacinamide above 35 mg/day, at least one of the Specific and/or the Dose-specific Use(s) or Purpose(s) indicated above is required.";s:12:"field_note_f";s:212:"Au moins un des usages ou fins recommandés spécifiques et/ou propre à la dose énumérés ci-dessus est requis dans le cas des produits fournissant une dose quotidienne de Niacinamide supérieure à 35 mg/jour";s:16:"field_legacy_nid";s:6:"100618";s:14:"field_workflow";s:9:"Published";s:5:"title";s:176:"NIA2_For products providing a daily dose of Niacinamide above 35 mg/day, at least one of the Specific and/or the Dose-specific Use(s) or Purpose(s) indicated above is required.";s:3:"nid";s:6:"215275";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215276;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"VIE_RRR";s:12:"field_note_e";s:605:"Vitamin E must be expressed as milligrams (mg) of 2R alpha- tocopherol (AT) irrespective of the source material used. See Appendix 1 for an explanation of this definition. For RRR-alpha-tocopherol and its esters (i.e. RRR-alpha-tocopherol, RRR-alpha-tocopheryl acetate, RRR-alpha-tocopheryl succinate): (i) 1 mg of RRR-alpha-Tocopherol = 1 mg AT of Vitamin E = 1.49 IU,  (ii) 1 mg of RRR-alpha-Tocopheryl acetate = 0.91 mg AT of Vitamin E = 1.36 IU,  (iii) 1 mg of RRR-alpha-Tocopheryl succinate = 0.81 mg AT of Vitamin E = 1.21 IU. (1 IU of RRR-alpha-tocopherol and its esters = 0.67 mg AT of Vitamin E).";s:12:"field_note_f";s:690:"La vitamine E doit être exprimée en milligrammes (mg) de 2R alpha-tocophérol (AT) sans égard à la matière d’origine utilisée. Consulter l’annexe 1 pour une explication de cette définition.    Pour (RRR)-alpha-tocophérol et ses esters (i.e. (RRR)-alpha-tocophérol, acétate de (RRR)-alpha-tocophéryle, succinate de (RRR)-alpha-tocophéryle) :  (i) 1 mg de RRR-alpha-tocophérol  =  1 mg AT de Vitamine E = 1.49 UI,  (ii) 1 mg d'Acétate de (RRR)-alpha-tocophéryle  =  0,91 mg AT de Vitamine E = 1,36 UI, (iii) 1 mg de Succinate de (RRR)-alpha-tocophéryle  =  0,81 mg AT de Vitamine E = 1,21 UI.  (1 UI de (RRR)-alpha-tocophérol et ses esters   =  0,67 mg AT de Vitamine E).";s:16:"field_legacy_nid";s:6:"100619";s:14:"field_workflow";s:9:"Published";s:5:"title";s:254:"VIE_RRR_Vitamin E must be expressed as milligrams (mg) of 2R alpha- tocopherol (AT) irrespective of the source material used. See Appendix 1 for an explanation of this definition. For RRR-alpha-tocopherol and its esters (i.e. RRR-alpha-tocopherol, RRR...";s:3:"nid";s:6:"215276";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215277;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"VIE_RAC";s:12:"field_note_e";s:640:"Vitamin E must be expressed as milligrams (mg) of 2R alpha- tocopherol (AT) irrespective of the source material used. See Appendix 1 for an explanation of this definition. For all rac-alpha-tocopherol and its esters (i.e. all rac-alpha-tocopherol, all rac-alpha-tocopheryl acetate, all rac-alpha-tocopheryl succinate): (i) 1 mg of All rac-alpha-tocopherol = 0.50 mg AT of Vitamin E = 1.10 IU,  (ii) 1 mg of All rac-alpha-tocopheryl acetate = 0.45 mg AT of Vitamin E = 1.00 IU,  (iii) 1 mg of All rac-alpha-tocopheryl succinate = 0.41 mg AT of Vitamin E = 0.89 IU. (1 IU of all rac-alpha-tocopherol and its esters = 0.45 mg AT of Vitamin E).";s:12:"field_note_f";s:765:"La vitamine E doit être exprimée en milligrammes (mg) de 2R alpha-tocophérol (AT) sans égard à la matière d’origine utilisée. Consulter l’annexe 1 pour une explication de cette définition.  Pour alpha-tocophérol totalement rac et ses esters (i.e. alpha-tocophérol totalement rac, acétate de alpha-tocophéryle totalement rac, succinate de alpha-tocophéryl totalement rac) :   (i) 1 mg d'Alpha-tocophérol totalement rac  =  0,50 mg AT de Vitamine E = 1,10 UI,  (ii) 1 mg d'Acétate d’alpha-tocophéryle totalement rac  =  0,45 mg AT de Vitamine E = 1,00 UI,  (iii) 1 mg de Succinate d’alpha-tocophéryle totalement rac  =  0,41 mg AT de Vitamine E = 0,89 UI.  (1 UI d'alpha-tocophérol totalement rac et ses esters  =  0,45 mg AT de Vitamine E).";s:16:"field_legacy_nid";s:6:"100620";s:14:"field_workflow";s:9:"Published";s:5:"title";s:246:"VIE_RAC_Vitamin E must be expressed as milligrams (mg) of 2R alpha- tocopherol (AT) irrespective of the source material used. See Appendix 1 for an explanation of this definition. For all rac-alpha-tocopherol and its esters (i.e. all rac-alpha...";s:3:"nid";s:6:"215277";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215278;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"MIN3";s:12:"field_note_e";s:157:"The daily minimum doses are based on approximately 5% of the highest RDA (IOM 2006). See Appendix 1 for definitions and Table 1 in Appendix 2 for RDA values.";s:12:"field_note_f";s:207:"Les valeurs minimales journalières représentent approximativement 5% de l'ANR le plus élevé (IOM 2006). Consulter l'annexe 1 pour les définitions et le tableau 1 de l'annexe 2 pour les valeurs de l'ANR.";s:16:"field_legacy_nid";s:6:"100621";s:14:"field_workflow";s:9:"Published";s:5:"title";s:162:"MIN3_The daily minimum doses are based on approximately 5% of the highest RDA (IOM 2006). See Appendix 1 for definitions and Table 1 in Appendix 2 for RDA values.";s:3:"nid";s:6:"215278";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215279;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"MAXVE";s:12:"field_note_e";s:81:"The maximum values are based on the Tolerable Upper Intake Level (UL) (IOM 2006).";s:12:"field_note_f";s:86:"Les valeurs maximales sont basées sur l’apport maximal tolérable (AMT) (IOM 2006).";s:16:"field_legacy_nid";s:6:"100622";s:14:"field_workflow";s:9:"Published";s:5:"title";s:87:"MAXVE_The maximum values are based on the Tolerable Upper Intake Level (UL) (IOM 2006).";s:3:"nid";s:6:"215279";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215280;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAXVE2";s:12:"field_note_e";s:232:"The maximum values are based on the Tolerable Upper Intake Level (UL) which applies to vitamin E intake from supplements only (IOM 2006).  These values have been modified for regulatory purposes. See Appendix 1 for more information.";s:12:"field_note_f";s:274:"Les valeurs maximales sont basées sur l’apport maximal tolérable (AMT) s’appliquant à la vitamine E sous forme de supplément uniquement (IOM 2006). Ces valeurs ont été modifiées pour des raisons règlementaires. Voir l’annexe 1 pour de plus amples informations.";s:16:"field_legacy_nid";s:6:"100623";s:14:"field_workflow";s:9:"Published";s:5:"title";s:239:"MAXVE2_The maximum values are based on the Tolerable Upper Intake Level (UL) which applies to vitamin E intake from supplements only (IOM 2006).  These values have been modified for regulatory purposes. See Appendix 1 for more information.";s:3:"nid";s:6:"215280";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215281;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"AGIN";s:12:"field_note_e";s:45:"Note: Alcohol-based extracts are not allowed.";s:12:"field_note_f";s:57:"Note: Les extraits à base d’alcool ne sont pas permis.";s:16:"field_legacy_nid";s:6:"100624";s:14:"field_workflow";s:9:"Published";s:5:"title";s:50:"AGIN_Note: Alcohol-based extracts are not allowed.";s:3:"nid";s:6:"215281";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215282;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"CLO";s:12:"field_note_e";s:135:"The potencies of vitamin A, vitamin D3 and/or EPA/DHA must be indicated on the PLA and label, in addition to the dose of Cod liver oil.";s:12:"field_note_f";s:185:"Les activités de la vitamine A, de la vitamine D3, et/ou de l’AEP et l’ADH, ainsi que la dose de l’huile de foie de morue, doivent être indiquées sur la DLMM et l’étiquette.";s:16:"field_legacy_nid";s:6:"100625";s:14:"field_workflow";s:9:"Published";s:5:"title";s:139:"CLO_The potencies of vitamin A, vitamin D3 and/or EPA/DHA must be indicated on the PLA and label, in addition to the dose of Cod liver oil.";s:3:"nid";s:6:"215282";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215283;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"CLO_GR";s:12:"field_note_e";s:168:"USP 32, Ph. Eur. 2008, or BP 2008 grade Cod Liver Oil must be used to ensure that potencies of vitamin A, vitamin D3, and EPA + DHA listed in Tables 2, 3 and 4 are met.";s:12:"field_note_f";s:242:"L’huile de foie de morue de catégorie USP 32, Ph. Eur. 2008, ou BP 2008 doit être utilisée pour garantir que les activités de la vitamine A, de la vitamine D3, et de l’AEP et l’ADH énoncées aux tableaux 2, 3 et 4 sont respectées.";s:16:"field_legacy_nid";s:6:"100626";s:14:"field_workflow";s:9:"Published";s:5:"title";s:175:"CLO_GR_USP 32, Ph. Eur. 2008, or BP 2008 grade Cod Liver Oil must be used to ensure that potencies of vitamin A, vitamin D3, and EPA + DHA listed in Tables 2, 3 and 4 are met.";s:3:"nid";s:6:"215283";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215284;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"CLO_MAX";s:12:"field_note_e";s:217:"For all subpopulations, the maximum dose is based on the quantity of Cod liver oil providing the maximum daily amount of vitamin A, in micrograms of RAE, according to the Tolerable Upper Intake Level (ULs) (IOM 2006).";s:12:"field_note_f";s:255:"Pour toutes les sous-populations, la dose maximale est établie à partir de la quantité d’huile de foie de morue fournissant le montant maximal quotidien de vitamine A en microgrammes d’EAR fondée sur l’apport maximal tolérable (AMT) (IOM 2006).";s:16:"field_legacy_nid";s:6:"100627";s:14:"field_workflow";s:9:"Published";s:5:"title";s:225:"CLO_MAX_For all subpopulations, the maximum dose is based on the quantity of Cod liver oil providing the maximum daily amount of vitamin A, in micrograms of RAE, according to the Tolerable Upper Intake Level (ULs) (IOM 2006).";s:3:"nid";s:6:"215284";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215285;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"CLO_MIN";s:12:"field_note_e";s:104:"The minimum dose of Cod liver oil is based on the minimum quantities of EPA + DHA required for efficacy.";s:12:"field_note_f";s:150:"La dose minimale d’huile de foie de morue est établie selon les quantités minimales d’AEP et d’ADH nécessaires à l’efficacité du produit.";s:16:"field_legacy_nid";s:6:"100628";s:14:"field_workflow";s:9:"Published";s:5:"title";s:112:"CLO_MIN_The minimum dose of Cod liver oil is based on the minimum quantities of EPA + DHA required for efficacy.";s:3:"nid";s:6:"215285";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215286;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"ALOE";s:12:"field_note_e";s:212:"For products which provide a dosage range, the following directions for use is considered optional: The correct individual dose is the smallest one required to produce a comfortable, soft-formed stool (EMEA 2006)";s:12:"field_note_f";s:210:"Pour les produits fournissant une gamme de posologies, le mode d'emploi suivant est facultatif: La posologie optimale est ajustée à la plus petite dose pour obtenir le passage d’une selle molle (EMEA 2006).";s:16:"field_legacy_nid";s:6:"100629";s:14:"field_workflow";s:9:"Published";s:5:"title";s:217:"ALOE_For products which provide a dosage range, the following directions for use is considered optional: The correct individual dose is the smallest one required to produce a comfortable, soft-formed stool (EMEA 2006)";s:3:"nid";s:6:"215286";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215287;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"BIODEF";s:12:"field_note_e";s:106:"Biotin deficiency is rare in North America (IOM 2006; Shils et al. 2006; Groff and Gropper 2000; IOM 1998)";s:12:"field_note_f";s:118:"Les carences en biotine sont rares en Amérique du Nord (IOM 2006; Shils et al. 2006; Groff et Gropper 2000; IOM 1998)";s:16:"field_legacy_nid";s:6:"100630";s:14:"field_workflow";s:9:"Published";s:5:"title";s:113:"BIODEF_Biotin deficiency is rare in North America (IOM 2006; Shils et al. 2006; Groff and Gropper 2000; IOM 1998)";s:3:"nid";s:6:"215287";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215288;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"IODDEF";s:12:"field_note_e";s:53:"Iodine deficiency is rare in North America (IOM 2006)";s:12:"field_note_f";s:63:"Les carences en iode sont rares en Amérique du Nord (IOM 2006)";s:16:"field_legacy_nid";s:6:"100631";s:14:"field_workflow";s:9:"Published";s:5:"title";s:60:"IODDEF_Iodine deficiency is rare in North America (IOM 2006)";s:3:"nid";s:6:"215288";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215289;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"SELDEF";s:12:"field_note_e";s:70:"Selenium deficiency is rare in North America (Groff and Gropper 2000).";s:12:"field_note_f";s:83:"Les carences en sélénium sont rares en Amérique du Nord (Groff et Gropper 2000).";s:16:"field_legacy_nid";s:6:"100632";s:14:"field_workflow";s:9:"Published";s:5:"title";s:77:"SELDEF_Selenium deficiency is rare in North America (Groff and Gropper 2000).";s:3:"nid";s:6:"215289";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215290;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"SENNA";s:12:"field_note_e";s:267:"For products which provide a dosage range, the following directions for use is considered optional: The correct individual dose is the smallest required to produce a comfortable, soft-formed stool (EMEA 2007a: EMEA2007b; ESCOP 2003; Blumenthal et al. 2000; WHO 1999).";s:12:"field_note_f";s:269:"Pour les produits fournissant une gamme de posologies, le mode d'emploi suivant est facultatif: La posologie optimale est ajustée à la plus petite dose pour obtenir le passage d’une selle molle  (EMEA 2007a: EMEA2007b; ESCOP 2003; Blumenthal et al. 2000; WHO 1999).";s:16:"field_legacy_nid";s:6:"100633";s:14:"field_workflow";s:9:"Published";s:5:"title";s:255:"SENNA_For products which provide a dosage range, the following directions for use is considered optional: The correct individual dose is the smallest required to produce a comfortable, soft-formed stool (EMEA 2007a: EMEA2007b; ESCOP 2003; Blumenthal et...";s:3:"nid";s:6:"215290";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215291;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"THIDEF";s:12:"field_note_e";s:109:"Thiamine deficiency is rare in North America (IOM 2006; Shils et al. 2006; Groff and Gropper 2000; IOM 1998).";s:12:"field_note_f";s:120:"Les carences en thiamine sont rares en Amérique du Nord (IOM 2006; Shils et al. 2006; Groff et Gropper 2000; IOM 1998).";s:16:"field_legacy_nid";s:6:"100634";s:14:"field_workflow";s:9:"Published";s:5:"title";s:116:"THIDEF_Thiamine deficiency is rare in North America (IOM 2006; Shils et al. 2006; Groff and Gropper 2000; IOM 1998).";s:3:"nid";s:6:"215291";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215292;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"VICDEF";s:12:"field_note_e";s:110:"Vitamin C deficiency is rare in North America (IOM 2006; Shils et al. 2006; Groff and Gropper 2000; IOM 2000).";s:12:"field_note_f";s:122:"Les carences en vitamine C sont rares en Amérique du Nord (IOM 2006; Shils et al. 2006; Groff et Gropper 2000; IOM 2000).";s:16:"field_legacy_nid";s:6:"100635";s:14:"field_workflow";s:9:"Published";s:5:"title";s:117:"VICDEF_Vitamin C deficiency is rare in North America (IOM 2006; Shils et al. 2006; Groff and Gropper 2000; IOM 2000).";s:3:"nid";s:6:"215292";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215293;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"VIEDEF";s:12:"field_note_e";s:100:"Vitamin E deficiency is rare in North America (IOM 2006; Shils et al. 2006; Groff and Gropper 2000).";s:12:"field_note_f";s:112:"La déficience en vitamine E est rare en Amérique du Nord (IOM 2006; Shils et al. 2006; Groff et Gropper 2000).";s:16:"field_legacy_nid";s:6:"100636";s:14:"field_workflow";s:9:"Published";s:5:"title";s:107:"VIEDEF_Vitamin E deficiency is rare in North America (IOM 2006; Shils et al. 2006; Groff and Gropper 2000).";s:3:"nid";s:6:"215293";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215294;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"CHR_1";s:12:"field_note_e";s:136:"When chromium picolinate is used as source material for elemental chromium, the product should be indicated for adult subpopulation only";s:12:"field_note_f";s:155:"Lorsque le picolinate de chrome est utilisé comme matière d’origine du chrome élémentaire, le produit est réservé à l’usage exclusif des adultes";s:16:"field_legacy_nid";s:6:"100637";s:14:"field_workflow";s:9:"Published";s:5:"title";s:142:"CHR_1_When chromium picolinate is used as source material for elemental chromium, the product should be indicated for adult subpopulation only";s:3:"nid";s:6:"215294";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215295;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"CHR_2";s:12:"field_note_e";s:142:"When chromium HAP chelate or chromium HVP chelate is used as source material, the product should be indicated for an adult subpopulation only.";s:12:"field_note_f";s:166:"Lorsque les produits de chélation de chrome et de PAH ou de PVH sont utilisés comme matière d’origine, le produit est réservé à l’usage exclusif des adultes";s:16:"field_legacy_nid";s:6:"100638";s:14:"field_workflow";s:9:"Published";s:5:"title";s:148:"CHR_2_When chromium HAP chelate or chromium HVP chelate is used as source material, the product should be indicated for an adult subpopulation only.";s:3:"nid";s:6:"215295";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215296;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"CHR_DEF";s:12:"field_note_e";s:74:"Chromium deficiency is rare in North America (IOM 2006; Shils et al. 2006)";s:12:"field_note_f";s:84:"Les carences en chrome sont rares en Amérique du Nord (IOM 2006; Shils et al. 2006)";s:16:"field_legacy_nid";s:6:"100639";s:14:"field_workflow";s:9:"Published";s:5:"title";s:82:"CHR_DEF_Chromium deficiency is rare in North America (IOM 2006; Shils et al. 2006)";s:3:"nid";s:6:"215296";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215297;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:8:"ADUL_CHR";s:12:"field_note_e";s:50:"Does not include pregnant and breastfeeding women.";s:12:"field_note_f";s:52:"Ne comprend pas les femmes enceintes et allaitantes.";s:16:"field_legacy_nid";s:6:"100640";s:14:"field_workflow";s:9:"Published";s:5:"title";s:59:"ADUL_CHR_Does not include pregnant and breastfeeding women.";s:3:"nid";s:6:"215297";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215298;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:9:"ADUL_ZINC";s:12:"field_note_e";s:106:"Adults includes pregnant and breastfeeding women, except for use of zinc picolinate (EFSA 2009; IOM 2001).";s:12:"field_note_f";s:132:"La sous-population adulte comprend les femmes enceintes et allaitantes,sauf dans le cas du picolinate de zinc (EFSA 2009; IOM 2001).";s:16:"field_legacy_nid";s:6:"100641";s:14:"field_workflow";s:9:"Published";s:5:"title";s:116:"ADUL_ZINC_Adults includes pregnant and breastfeeding women, except for use of zinc picolinate (EFSA 2009; IOM 2001).";s:3:"nid";s:6:"215298";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215299;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"ZINC_1";s:12:"field_note_e";s:123:"When zinc picolinate is used as a source of elemental zinc, the product should be indicated for an adult subpopulation only";s:12:"field_note_f";s:151:"Lorsque le picolinate de zinc est utilisé comme matière d’origine du zinc élémentaire, le produit est réservé à l’usage exclusif des adultes";s:16:"field_legacy_nid";s:6:"100642";s:14:"field_workflow";s:9:"Published";s:5:"title";s:130:"ZINC_1_When zinc picolinate is used as a source of elemental zinc, the product should be indicated for an adult subpopulation only";s:3:"nid";s:6:"215299";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215300;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"ZINC_3";s:12:"field_note_e";s:144:"When zinc HAP chelate or zinc HVP chelate is used as a source of elemental zinc, the product should be indicated for an adult subpopulation only";s:12:"field_note_f";s:165:"Lorsque les produits de chélation de zinc et de PAH ou de PVH sont utilisés comme matière d’origine, le produit est réservé à l’usage exclusif des adultes.";s:16:"field_legacy_nid";s:6:"100643";s:14:"field_workflow";s:9:"Published";s:5:"title";s:151:"ZINC_3_When zinc HAP chelate or zinc HVP chelate is used as a source of elemental zinc, the product should be indicated for an adult subpopulation only";s:3:"nid";s:6:"215300";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215301;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"ZIN_DEF";s:12:"field_note_e";s:80:"Zinc deficiency is rare in North America (IOM 2006; Shils et al. 2006; IOM 2001)";s:12:"field_note_f";s:92:"Les carences en zinc sont rares en Amérique du Nord (IOM 2006; Shils et al. 2006; IOM 2001)";s:16:"field_legacy_nid";s:6:"100644";s:14:"field_workflow";s:9:"Published";s:5:"title";s:88:"ZIN_DEF_Zinc deficiency is rare in North America (IOM 2006; Shils et al. 2006; IOM 2001)";s:3:"nid";s:6:"215301";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215302;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"CLA_AI";s:12:"field_note_e";s:347:"Additional information not to be submitted with the compendial PLA (although the quantity of CLA-rich oil may be requested at the NHPD’s discretion): Approximately 4-6.5 g CLA-rich oil provides 3-5 g CLA.  See the information in the Specifications section for detailed information on the required proportions of the c9t11 and t10c12 CLA isomers.";s:12:"field_note_f";s:403:"L’information suivante n’a pas à être fournie avec la demande de licence selon la voie officinale (mais la quantité d’huile riche en ALC pourrait être requise à la discrétion de la DPSN) : environ 4 à 6,5 g d’huile riche en ALC fournissent 3 à 5 g d’ALC. Consulter la section des spécifications pour obtenir plus de détails au sujet des taux d’isomères c9t11 et t10c12 de l’ALC.";s:16:"field_legacy_nid";s:6:"100645";s:14:"field_workflow";s:9:"Published";s:5:"title";s:244:"CLA_AI_Additional information not to be submitted with the compendial PLA (although the quantity of CLA-rich oil may be requested at the NHPD’s discretion): Approximately 4-6.5 g CLA-rich oil provides 3-5 g CLA.  See the information in the...";s:3:"nid";s:6:"215302";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215303;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"CLA_OF";s:12:"field_note_e";s:104:"The following directions of use is optional:  Take with food. (Watras et al. 2007; Kamphuis et al. 2003)";s:12:"field_note_f";s:121:"Le mode d'emploi suivant est facultatif:  Prendre avec de la nourriture. (Watras et collab 2007; Kamphuis et collab 2003)";s:16:"field_legacy_nid";s:6:"100646";s:14:"field_workflow";s:9:"Published";s:5:"title";s:111:"CLA_OF_The following directions of use is optional:  Take with food. (Watras et al. 2007; Kamphuis et al. 2003)";s:3:"nid";s:6:"215303";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215304;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"VAL";s:12:"field_note_e";s:346:"For sleep aid products, the following directions of use are optional:  (i) Take a single dose 30 to 60 minutes before bedtime (Ziegler et al. 2002; Dominguez et al. 2000; Donath et al. 2000; Balderer and Borbély 1985; Leathwood and Chauffard 1985; Leathwood et al. 1982).    (ii) Take an earlier dose during the evening if necessary (EMEA 2006).";s:12:"field_note_f";s:346:"Pour les aide-sommeil, les modes d'emploi suivants sont facultatifs:  (i) Prendre une seule dose 30 à 60 minutes avant le coucher (Ziegler et al. 2002; Dominguez et al. 2000; Donath et al. 2000; Balderer et Borbély 1985; Leathwood et Chauffard 1985; Leathwood et al. 1982).      (ii) Prendre une dose plus tôt en soirée au besoin (EMEA 2006).";s:16:"field_legacy_nid";s:6:"100647";s:14:"field_workflow";s:9:"Published";s:5:"title";s:255:"VAL_For sleep aid products, the following directions of use are optional:  (i) Take a single dose 30 to 60 minutes before bedtime (Ziegler et al. 2002; Dominguez et al. 2000; Donath et al. 2000; Balderer and Borbély 1985; Leathwood and Chauffard 1985;...";s:3:"nid";s:6:"215304";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215305;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"MIN_VIA";s:12:"field_note_e";s:189:"The daily minimum doses are based on approximately 5% of the highest RDA or AI for vitamin A(IOM 2006). See Appendix 1 for definitions and Table 3 in Appendix 2 for RDA values and AI values";s:12:"field_note_f";s:236:"Ces valeurs représentent approximativement 5 % de l’AS ou de l’ANR les plus élevés, pour la vitamine A (IOM 2006). Consulter l'annexe 1 pour les définitions et le tableau 3 de l'annexe 2 pour les valeurs de l’AS et de l’ANR.";s:16:"field_legacy_nid";s:6:"100648";s:14:"field_workflow";s:9:"Published";s:5:"title";s:197:"MIN_VIA_The daily minimum doses are based on approximately 5% of the highest RDA or AI for vitamin A(IOM 2006). See Appendix 1 for definitions and Table 3 in Appendix 2 for RDA values and AI values";s:3:"nid";s:6:"215305";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215306;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"BETDOS";s:12:"field_note_e";s:212:"Beta-carotene doses were derived from the conversion factor of 6 µg of beta-carotene = 1 µg all-trans retinol; hence, a ratio of 6:1 beta-carotene:vitamin A, on a weight to weight basis (HC 1990; FAO/WHO 1967).";s:12:"field_note_f";s:227:"Les doses de bêta-carotène sont calculées à l’aide du facteur de conversion 6 µg bêta-carotène = 1 µg rétinol tout-trans; ainsi, un ratio de 6:1 bêta-carotène : vitamine A, poids pour poids (SC 1990; FAO/WHO 1967).";s:16:"field_legacy_nid";s:6:"100649";s:14:"field_workflow";s:9:"Published";s:5:"title";s:219:"BETDOS_Beta-carotene doses were derived from the conversion factor of 6 µg of beta-carotene = 1 µg all-trans retinol; hence, a ratio of 6:1 beta-carotene:vitamin A, on a weight to weight basis (HC 1990; FAO/WHO 1967).";s:3:"nid";s:6:"215306";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215307;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"CAS_DR";s:12:"field_note_e";s:213:"The following directions of use is optional: (for products which provide a dosage range): The correct individual dose is the smallest required to produce a comfortable soft-formed stool (EMEA 2007; McGuffin 1997).";s:12:"field_note_f";s:199:"Facultatif (pour les produits fournissant une gamme de posologies) : La posologie optimale est ajustée à la plus petite dose pour obtenir le passage d’une selle molle (EMEA 2007 ; McGuffin 1997).";s:16:"field_legacy_nid";s:6:"100650";s:14:"field_workflow";s:9:"Published";s:5:"title";s:220:"CAS_DR_The following directions of use is optional: (for products which provide a dosage range): The correct individual dose is the smallest required to produce a comfortable soft-formed stool (EMEA 2007; McGuffin 1997).";s:3:"nid";s:6:"215307";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215308;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FLAXS_1";s:12:"field_note_e";s:243:"Children and adolescent doses were calculated as a proportion of the adult dose (ESCOP 2003; Boon 2000). The use of Flaxseed in children and adolescents is supported by the following references: ESCOP 2003; Boon 2000; Bove 2001; Schilcher 1997";s:12:"field_note_f";s:272:"Les doses pour les enfants et les adolescents ont été calculées à partir d’une fraction de la dose adulte (ESCOP 2003; Boon 2000). Les références suivantes appuient l’emploi de la graine de lin chez les enfants : ESCOP 2003; Boon 2000; Bove 2001; Schilcher 1997.";s:16:"field_legacy_nid";s:6:"100651";s:14:"field_workflow";s:9:"Published";s:5:"title";s:251:"FLAXS_1_Children and adolescent doses were calculated as a proportion of the adult dose (ESCOP 2003; Boon 2000). The use of Flaxseed in children and adolescents is supported by the following references: ESCOP 2003; Boon 2000; Bove 2001; Schilcher 1997";s:3:"nid";s:6:"215308";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215309;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FLAXS_2";s:12:"field_note_e";s:163:"Adult dose supported by the following references: Patade et al. 2008; EMEA 2006; IOM 2006; ESCOP 2003; Lucas et al. 2002; Jenkins et al. 1999; Cunnane et al. 1993.";s:12:"field_note_f";s:189:"Les références suivantes ont servi à établir la dose pour les adultes : Patade et al. 2008; EMEA 2006; IOM 2006; ESCOP 2003; Lucas et al. 2002; Jenkins et al. 1999; Cunnane et al. 1993.";s:16:"field_legacy_nid";s:6:"100652";s:14:"field_workflow";s:9:"Published";s:5:"title";s:171:"FLAXS_2_Adult dose supported by the following references: Patade et al. 2008; EMEA 2006; IOM 2006; ESCOP 2003; Lucas et al. 2002; Jenkins et al. 1999; Cunnane et al. 1993.";s:3:"nid";s:6:"215309";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215310;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FLAXS_3";s:12:"field_note_e";s:74:"Includes pregnant and breastfeeding women (Mills et al. 2006; ESCOP 2003).";s:12:"field_note_f";s:78:"Y compris les femmes enceintes et allaitantes (Mills et al. 2006; ESCOP 2003).";s:16:"field_legacy_nid";s:6:"100653";s:14:"field_workflow";s:9:"Published";s:5:"title";s:82:"FLAXS_3_Includes pregnant and breastfeeding women (Mills et al. 2006; ESCOP 2003).";s:3:"nid";s:6:"215310";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215311;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FLAXS_4";s:12:"field_note_e";s:137:"If potencies are declared, the only acceptable potencies are: 
(I)20-30 % ALA (CGC 2008; HC 2008; Cunnane 1993);  (ii) 5-7 % LA (HC 2008)";s:12:"field_note_f";s:142:"Si déclarées, les seules activités acceptables sont: (I) 20 à 30 % d’AAL (CCG 2008; SC 2008; Cunnane 1993);  (ii) 5-7 % d’AL (SC 2008)";s:16:"field_legacy_nid";s:6:"100654";s:14:"field_workflow";s:9:"Published";s:5:"title";s:145:"FLAXS_4_If potencies are declared, the only acceptable potencies are: 
(I)20-30 % ALA (CGC 2008; HC 2008; Cunnane 1993);  (ii) 5-7 % LA (HC 2008)";s:3:"nid";s:6:"215311";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215312;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:9:"FLAXS_DR1";s:12:"field_note_e";s:168:"The following directions of use is optional: ( For products with dose greater or equal to 5 g/day) Take during the day (, not immediately prior to bedtime) (EMEA 2006).";s:12:"field_note_f";s:179:"Facultatif (pour les produits fournissant une dose supérieure ou égale à 5 g/jour): Prendre au cours de la journée (ne pas prendre immédiatement avant le coucher) (EMEA 2006)";s:16:"field_legacy_nid";s:6:"100655";s:14:"field_workflow";s:9:"Published";s:5:"title";s:178:"FLAXS_DR1_The following directions of use is optional: ( For products with dose greater or equal to 5 g/day) Take during the day (, not immediately prior to bedtime) (EMEA 2006).";s:3:"nid";s:6:"215312";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215313;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:9:"FLAXS_DR2";s:12:"field_note_e";s:199:"The following directions of use is optional: (for laxative products which provide a dosage range): Minimum daily dose may be increased, up to the maximum daily dose, until desired effect is obtained.";s:12:"field_note_f";s:237:"Facultatif (pour les produits laxatifs fournissant une gamme de posologies) : : La dose quotidienne minimale peut être augmentée graduellement jusqu'à ce que l’effet désiré soit obtenu, sans dépasser la dose quotidienne maximale.";s:16:"field_legacy_nid";s:6:"100656";s:14:"field_workflow";s:9:"Published";s:5:"title";s:209:"FLAXS_DR2_The following directions of use is optional: (for laxative products which provide a dosage range): Minimum daily dose may be increased, up to the maximum daily dose, until desired effect is obtained.";s:3:"nid";s:6:"215313";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215314;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FLAXO_1";s:12:"field_note_e";s:165:"Children and adolescent doses were calculated as a proportion of the adult dose (JC 2008). The use of Flax oil in children and adolescents is supported by Bove 2001.";s:12:"field_note_f";s:222:"Les doses pour les enfants et les adolescents ont été calculées à partir d’une fraction de la dose adulte (JC 2008). La référence Bove 2001 appuie l’emploi de l’huile de lin chez les enfants et les adolescents.";s:16:"field_legacy_nid";s:6:"100657";s:14:"field_workflow";s:9:"Published";s:5:"title";s:173:"FLAXO_1_Children and adolescent doses were calculated as a proportion of the adult dose (JC 2008). The use of Flax oil in children and adolescents is supported by Bove 2001.";s:3:"nid";s:6:"215314";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215315;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FLAXO_2";s:12:"field_note_e";s:144:"Adult dose supported by the following references: IOM 2006; Schwab et al. 2006; Nordström et al. 1995; Kelley et al. 1993; Fischer et al. 1984.";s:12:"field_note_f";s:170:"Les références suivantes ont servi à établir la dose pour les adultes : IOM 2006; Schwab et al. 2006; Nordström et al. 1995; Kelley et al. 1993; Fischer et al. 1984.";s:16:"field_legacy_nid";s:6:"100658";s:14:"field_workflow";s:9:"Published";s:5:"title";s:152:"FLAXO_2_Adult dose supported by the following references: IOM 2006; Schwab et al. 2006; Nordström et al. 1995; Kelley et al. 1993; Fischer et al. 1984.";s:3:"nid";s:6:"215315";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215316;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FLAXO_3";s:12:"field_note_e";s:62:"Includes pregnant and breastfeeding women (Mills et al. 2006).";s:12:"field_note_f";s:66:"Y compris les femmes enceintes et allaitantes (Mills et al. 2006).";s:16:"field_legacy_nid";s:6:"100659";s:14:"field_workflow";s:9:"Published";s:5:"title";s:70:"FLAXO_3_Includes pregnant and breastfeeding women (Mills et al. 2006).";s:3:"nid";s:6:"215316";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215317;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FLAXO_4";s:12:"field_note_e";s:192:"If potencies are declared, the only acceptable potencies are as follows: 
A) 35-65 % ALA (CGC 2008; HC 2008; Ph. Eur. 2008; Hoffmann 2003); B)11-24 % LA (HC 2008; Ph. Eur. 2008; Hoffmann 2003)";s:12:"field_note_f";s:188:"Si déclarées, les seules activités acceptables sont:
A) 35 à 65 % d’AAL (CCG 2008; Ph. Eur. 2008; SC 2008; Hoffmann 2003);  B)11 à 24 % d’AL (Ph Eur. 2008; SC 2008; Hoffmann 2003)";s:16:"field_legacy_nid";s:6:"100660";s:14:"field_workflow";s:9:"Published";s:5:"title";s:200:"FLAXO_4_If potencies are declared, the only acceptable potencies are as follows: 
A) 35-65 % ALA (CGC 2008; HC 2008; Ph. Eur. 2008; Hoffmann 2003); B)11-24 % LA (HC 2008; Ph. Eur. 2008; Hoffmann 2003)";s:3:"nid";s:6:"215317";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215318;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FLAXO_5";s:12:"field_note_e";s:131:"The following potency is considered as additional information and can be included on the label:
  11-35% oleic acid (Ph. Eur. 2008)";s:12:"field_note_f";s:155:"L’activité suivante est considérée comme renseignement supplémentaire qui peut être inclus à l’étiquette :
    11-35% oleic acid (Ph. Eur. 2008)";s:16:"field_legacy_nid";s:6:"100661";s:14:"field_workflow";s:9:"Published";s:5:"title";s:139:"FLAXO_5_The following potency is considered as additional information and can be included on the label:
  11-35% oleic acid (Ph. Eur. 2008)";s:3:"nid";s:6:"215318";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215319;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"MAGDEF";s:12:"field_note_e";s:164:"The use or purpose statement "Helps to prevent magnesium deficiency" does not apply to the following subpopulations: Children 1-8 years and Adolescents 14-18 years.";s:12:"field_note_f";s:164:"L'usage ou fin recommandé "Aide à prévenir la carence en magnésium" ne s'applique pas aux sous-populations suivantes:  Enfants 1-8 ans et Adolescents 14-18 ans.";s:16:"field_legacy_nid";s:6:"100662";s:14:"field_workflow";s:9:"Published";s:5:"title";s:171:"MAGDEF_The use or purpose statement "Helps to prevent magnesium deficiency" does not apply to the following subpopulations: Children 1-8 years and Adolescents 14-18 years.";s:3:"nid";s:6:"215319";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215320;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"EPEDH_1";s:12:"field_note_e";s:38:"See Appendix 2 for dosage information.";s:12:"field_note_f";s:54:"Consulter l'annexe 2 pour l'information sur les doses.";s:16:"field_legacy_nid";s:6:"100663";s:14:"field_workflow";s:9:"Published";s:5:"title";s:46:"EPEDH_1_See Appendix 2 for dosage information.";s:3:"nid";s:6:"215320";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215321;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"PSEUC";s:12:"field_note_e";s:46:"See Appendices 1 and 2 for dosage information.";s:12:"field_note_f";s:62:"Consulter les annexes 1 et 2 pour l'information sur les doses.";s:16:"field_legacy_nid";s:6:"100664";s:14:"field_workflow";s:9:"Published";s:5:"title";s:52:"PSEUC_See Appendices 1 and 2 for dosage information.";s:3:"nid";s:6:"215321";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215322;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"PSEUA";s:12:"field_note_e";s:38:"See Appendix 1 for dosage information.";s:12:"field_note_f";s:54:"Consulter l'annexe 1 pour l'information sur les doses.";s:16:"field_legacy_nid";s:6:"100665";s:14:"field_workflow";s:9:"Published";s:5:"title";s:44:"PSEUA_See Appendix 1 for dosage information.";s:3:"nid";s:6:"215322";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215323;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"LEPHED";s:12:"field_note_e";s:38:"See Appendix 1 for dosage information.";s:12:"field_note_f";s:54:"Consulter l'annexe 1 pour l'information sur les doses.";s:16:"field_legacy_nid";s:6:"100666";s:14:"field_workflow";s:9:"Published";s:5:"title";s:45:"LEPHED_See Appendix 1 for dosage information.";s:3:"nid";s:6:"215323";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215324;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"CHASED";s:12:"field_note_e";s:136:"See Appendix 1 for examples of appropriate dosage preparations, frequencies of use and directions for use, according to cited references";s:12:"field_note_f";s:137:"Consulter l’annexe 1 pour des exemples de préparations de doses, de fréquences et de modes d’emploi, selon les références citées";s:16:"field_legacy_nid";s:6:"100667";s:14:"field_workflow";s:9:"Published";s:5:"title";s:143:"CHASED_See Appendix 1 for examples of appropriate dosage preparations, frequencies of use and directions for use, according to cited references";s:3:"nid";s:6:"215324";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215325;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"DGLO_1";s:12:"field_note_e";s:218:"Children and adolescent doses were calculated as a fraction of the adult dose (JC 2008).The use of licorice in children and adolescents is supported by the following references: McIntyre 2005; Schilcher 1997; Bove 1996";s:12:"field_note_f";s:274:"Les doses pour les enfants et les adolescents ont été calculées par une fraction de la dose pour adultes (JC 2008). L’utilisation de la réglisse chez les enfants et les adolescents est appuyée par les références suivantes : McIntyre 2005; Schilcher 1997; Bove 1996.";s:16:"field_legacy_nid";s:6:"100668";s:14:"field_workflow";s:9:"Published";s:5:"title";s:225:"DGLO_1_Children and adolescent doses were calculated as a fraction of the adult dose (JC 2008).The use of licorice in children and adolescents is supported by the following references: McIntyre 2005; Schilcher 1997; Bove 1996";s:3:"nid";s:6:"215325";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215326;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"DGLO_2";s:12:"field_note_e";s:53:"Adult doses are supported by Pizzorno and Murray 2006";s:12:"field_note_f";s:56:"Les doses adultes proviennent de Pizzorno et Murray 2006";s:16:"field_legacy_nid";s:6:"100669";s:14:"field_workflow";s:9:"Published";s:5:"title";s:60:"DGLO_2_Adult doses are supported by Pizzorno and Murray 2006";s:3:"nid";s:6:"215326";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215327;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"DGLB_1";s:12:"field_note_e";s:219:"Children and adolescent doses were calculated as a fraction of the adult dose (JC 2008). The use of licorice in children and adolescents is supported by the following references: McIntyre 2005; Schilcher 1997; Bove 1996";s:12:"field_note_f";s:274:"Les doses pour les enfants et les adolescents ont été calculées par une fraction de la dose pour adultes (JC 2008). L’utilisation de la réglisse chez les enfants et les adolescents est appuyée par les références suivantes : McIntyre 2005; Schilcher 1997; Bove 1996.";s:16:"field_legacy_nid";s:6:"100670";s:14:"field_workflow";s:9:"Published";s:5:"title";s:226:"DGLB_1_Children and adolescent doses were calculated as a fraction of the adult dose (JC 2008). The use of licorice in children and adolescents is supported by the following references: McIntyre 2005; Schilcher 1997; Bove 1996";s:3:"nid";s:6:"215327";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215328;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"DGLB_2";s:12:"field_note_e";s:53:"Adult doses are supported by Pizzorno and Murray 2006";s:12:"field_note_f";s:78:"Les doses adultes proviennent de Pizzorno et Murray 2006 et de Das et al. 1989";s:16:"field_legacy_nid";s:6:"100671";s:14:"field_workflow";s:9:"Published";s:5:"title";s:60:"DGLB_2_Adult doses are supported by Pizzorno and Murray 2006";s:3:"nid";s:6:"215328";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215329;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"FEV";s:12:"field_note_e";s:79:"Note: The daily dose is not to exceed 4 mg of parthenolide (Curry et al. 2004).";s:12:"field_note_f";s:91:"Nota: La dose quotidienne ne doit pas dépassée 4 mg de parthénolide (Curry et al. 2004).";s:16:"field_legacy_nid";s:6:"100672";s:14:"field_workflow";s:9:"Published";s:5:"title";s:83:"FEV_Note: The daily dose is not to exceed 4 mg of parthenolide (Curry et al. 2004).";s:3:"nid";s:6:"215329";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215330;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"EPAP1";s:12:"field_note_e";s:173:"Refer to Appendix 1 for examples of dosage preparations, and directions for use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:12:"field_note_f";s:189:"Consulter l’annexe 1 pour des exemples pertinents de préparations posologiques, et de modes d’emploi, selon les références citées. L’annexe 1 a pour objet de guider l’industrie.";s:16:"field_legacy_nid";s:6:"100673";s:14:"field_workflow";s:9:"Published";s:5:"title";s:179:"EPAP1_Refer to Appendix 1 for examples of dosage preparations, and directions for use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:3:"nid";s:6:"215330";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215331;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"APP1R";s:12:"field_note_e";s:172:"Refer to Appendix 1 for examples of dosage preparations and frequencies of use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:12:"field_note_f";s:171:"Consulter l'annexe 1 pour des exemples de préparations de doses et de fréquences d'emploi, selon les références citées. L'annexe 1 a pour objet de guider l'industrie.";s:16:"field_legacy_nid";s:6:"100674";s:14:"field_workflow";s:9:"Published";s:5:"title";s:178:"APP1R_Refer to Appendix 1 for examples of dosage preparations and frequencies of use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:3:"nid";s:6:"215331";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215332;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"RESMIN";s:12:"field_note_e";s:80:"Restrictions to minimum dose may apply according to Use(s) or Purpose(s) section";s:12:"field_note_f";s:106:"Certaines restrictions aux doses minimales peuvent s’appliquer selon les usage(s) ou fin(s) recommandés";s:16:"field_legacy_nid";s:6:"100675";s:14:"field_workflow";s:9:"Published";s:5:"title";s:87:"RESMIN_Restrictions to minimum dose may apply according to Use(s) or Purpose(s) section";s:3:"nid";s:6:"215332";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215333;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"PORIA";s:12:"field_note_e";s:153:"Refer to Appendix 1 for examples of appropriate dosage preparations and frequencies of use. The purpose of Appendix 1 is to provide guidance to industry.";s:12:"field_note_f";s:140:"Consulter l’annexe 1 pour des exemples de préparations posologiques et de fréquences. L’annexe 1 a pour objet de guider l’industrie.";s:16:"field_legacy_nid";s:6:"100676";s:14:"field_workflow";s:9:"Published";s:5:"title";s:159:"PORIA_Refer to Appendix 1 for examples of appropriate dosage preparations and frequencies of use. The purpose of Appendix 1 is to provide guidance to industry.";s:3:"nid";s:6:"215333";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215334;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"DONG";s:12:"field_note_e";s:73:"Refer to Appendix 1 for the TCM method of preparation for Dong quai root.";s:12:"field_note_f";s:66:"Consulter l’annexe 1 pour la préparation des racines traitées.";s:16:"field_legacy_nid";s:6:"100677";s:14:"field_workflow";s:9:"Published";s:5:"title";s:78:"DONG_Refer to Appendix 1 for the TCM method of preparation for Dong quai root.";s:3:"nid";s:6:"215334";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215335;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"LYC";s:12:"field_note_e";s:54:"Products must contain more than 95% lycopene (USP 32).";s:12:"field_note_f";s:64:"Les produits doivent contenir plus de 95% de lycopène (USP 32).";s:16:"field_legacy_nid";s:6:"100678";s:14:"field_workflow";s:9:"Published";s:5:"title";s:58:"LYC_Products must contain more than 95% lycopene (USP 32).";s:3:"nid";s:6:"215335";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215336;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"ENZYME";s:12:"field_note_e";s:337:"Dose unit information must include the quantities of both the enzyme preparation (mg or ml) and its enzymatic activity (FCC or USP units).  When submitting by ePLA, please put the enzymatic activity quantity in the Quantity/Unit fields (field 77) and the quantity of enzyme preparation in mg or ml in the Additional Quantity/Unit fields.";s:12:"field_note_f";s:386:"L'information sur la dose doit inclure la quantité de la préparation d'enzymes (mg ou ml) ainsi que son activité enzymatique (unités FCC ou USP).  Si la présentation est par DLMM-e, veuillez mettre l'activité enzymatique dans les champs de Quantité/Unité (champ 77) et la quantité de la préparation d'enzymes en mg ou en ml dans les champs Quantités/Unités supplémentaires.";s:16:"field_legacy_nid";s:6:"100679";s:14:"field_workflow";s:9:"Published";s:5:"title";s:255:"ENZYME_Dose unit information must include the quantities of both the enzyme preparation (mg or ml) and its enzymatic activity (FCC or USP units).  When submitting by ePLA, please put the enzymatic activity quantity in the Quantity/Unit fields (field 77...";s:3:"nid";s:6:"215336";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215337;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"ALPHA";s:12:"field_note_e";s:204:"One alpha-amylase dextrinizing unit (DU) is defined as the quantity of alpha-amylase that will dextrinize soluble starch in the presence of an excess of beta-amylase at the rate of 1 g/h at 30ºC (FCC 8).";s:12:"field_note_f";s:230:"Une unité dextrinifiante d’alpha-amylase (DU) est définie comme étant la quantité d’alpha-amylase qui peut dextrinifier de l’amidon soluble en présence d’un excès de bêta-amylase à un taux de 1g/h à 30ºC (FCC 8).";s:16:"field_legacy_nid";s:6:"100680";s:14:"field_workflow";s:9:"Published";s:5:"title";s:210:"ALPHA_One alpha-amylase dextrinizing unit (DU) is defined as the quantity of alpha-amylase that will dextrinize soluble starch in the presence of an excess of beta-amylase at the rate of 1 g/h at 30ºC (FCC 8).";s:3:"nid";s:6:"215337";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215338;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"FRBR1";s:12:"field_note_e";s:282:"One papain unit (PU) is defined as that quantity of enzyme that liberates the equivalent of 1 µg of tyrosine per hour under the conditions of the assay (FCC 8).  One gelatin digestion unit (GDU) is approximately equivalent to 15 000 FCC papain unit (1 GDU = approx. 15 000 FCC PU).";s:12:"field_note_f";s:326:"Une unité de papaïne (UP) est définie comme étant la quantité d’enzymes qui libère l’équivalent de1 µg de tyrosine à l’heure dans les conditions du test (FCC 8).  Une unité de dissolution de gélatine (UDG) est approximativement équivalente à 15 000 unité de papaïne du FCC (1 UGD = approx. 15 000 FCC PU).";s:16:"field_legacy_nid";s:6:"100681";s:14:"field_workflow";s:9:"Published";s:5:"title";s:253:"FRBR1_One papain unit (PU) is defined as that quantity of enzyme that liberates the equivalent of 1 µg of tyrosine per hour under the conditions of the assay (FCC 8).  One gelatin digestion unit (GDU) is approximately equivalent to 15 000 FCC papain...";s:3:"nid";s:6:"215338";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215339;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"FRBR2";s:12:"field_note_e";s:204:"For multi-ingredient products containing both Papain and Bromelain (fruit and/ or stem), the combined proteolytic activity should not exceed the maximum proteolytic activity of 130 000 000 FCC PU per day.";s:12:"field_note_f";s:246:"Pour les produits à ingrédients multiples qui contiennent de la papaïne et de la bromelaïne (fruit et/ou tige), l’activité protéolytique combinée ne doit pas dépasser l’activité protéolytique maximale de 130 000 000 FCC PU par jour.";s:16:"field_legacy_nid";s:6:"100682";s:14:"field_workflow";s:9:"Published";s:5:"title";s:210:"FRBR2_For multi-ingredient products containing both Papain and Bromelain (fruit and/ or stem), the combined proteolytic activity should not exceed the maximum proteolytic activity of 130 000 000 FCC PU per day.";s:3:"nid";s:6:"215339";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215340;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"CELL";s:12:"field_note_e";s:213:"One cellulase unit (CU) is defined as the amount of activity that will produce a relative fluidity change of 1 in 5 minutes in a defined carboxymethyl cellulose substrate under the conditions of the assay (FCC 8).";s:12:"field_note_f";s:256:"Une unité de cellulase (UC) est définie comme étant la quantité d’activité qui produit un changement relatif de fluidité de 1 durant un intervalle de 5 minutes pour un substrat défini de carboxyméthylcellulose dans les conditions du test (FCC 8).";s:16:"field_legacy_nid";s:6:"100683";s:14:"field_workflow";s:9:"Published";s:5:"title";s:218:"CELL_One cellulase unit (CU) is defined as the amount of activity that will produce a relative fluidity change of 1 in 5 minutes in a defined carboxymethyl cellulose substrate under the conditions of the assay (FCC 8).";s:3:"nid";s:6:"215340";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215341;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"CHYM";s:12:"field_note_e";s:152:"One USP Chymotrypsin Unit is defined as the activity causing a change in absorbance at the rate of 0.0075/min under the conditions of the assay (FCC 8).";s:12:"field_note_f";s:173:"Une unité de chymotrypsine USP est définie comme étant l’activité causant un changement de l’absorbance à un taux de 0.0075/min dans les conditions du test (FCC 8).";s:16:"field_legacy_nid";s:6:"100684";s:14:"field_workflow";s:9:"Published";s:5:"title";s:157:"CHYM_One USP Chymotrypsin Unit is defined as the activity causing a change in absorbance at the rate of 0.0075/min under the conditions of the assay (FCC 8).";s:3:"nid";s:6:"215341";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215342;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FUNPRO1";s:12:"field_note_e";s:327:"FCC 8: One hemoglobin unit on the tyrosine basis (HUT) of proteolytic (protease) activity is defined as that amount of enzyme that produces, in 1 minute under the conditions of the assay, a hydrolysate whose absorbance at 275 nm is the same as that of a solution containing 1.10 mcg/mL of tyrosine in 0.006 N hydrochloric acid.";s:12:"field_note_f";s:360:"FCC 8: Une unité d’hémoglobine basée sur la tyrosine (HUT) d’activité protéolytique (protéase) est définie comme étant la quantité d’enzymes qui produit, en une minute dans les conditions du test, un hydrolysat dont l’absorbance à 275 nm est la même qu’une solution renfermant 1,10 mcg/mL de tyrosine dans 0,006 N d’acide hydrochlorique.";s:16:"field_legacy_nid";s:6:"100685";s:14:"field_workflow";s:9:"Published";s:5:"title";s:254:"FUNPRO1_FCC 8: One hemoglobin unit on the tyrosine basis (HUT) of proteolytic (protease) activity is defined as that amount of enzyme that produces, in 1 minute under the conditions of the assay, a hydrolysate whose absorbance at 275 nm is the same as...";s:3:"nid";s:6:"215342";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215343;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FUNPRO2";s:12:"field_note_e";s:159:"FCC 8: One spectrophotometric acid protease unit (SAP) is that activity that will liberate 1 micromol of tyrosine per minute under the conditions of the assay.";s:12:"field_note_f";s:180:"FCC 8: Une unité spectrophotométrique d’acide protéase (SAP) est définie comme étant l’activité qui libère 1 micromol de tyrosine par minute dans les conditions du test.";s:16:"field_legacy_nid";s:6:"100686";s:14:"field_workflow";s:9:"Published";s:5:"title";s:167:"FUNPRO2_FCC 8: One spectrophotometric acid protease unit (SAP) is that activity that will liberate 1 micromol of tyrosine per minute under the conditions of the assay.";s:3:"nid";s:6:"215343";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215344;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FUNPRO3";s:12:"field_note_e";s:216:"For multi-ingredient products containing protease from A. niger and protease from A. oryzae, the maximum proteolytic activity from both sources cannot exceed 680000 FCC HUT per day and/or 6800 FCCSAP per day (FCC 8).";s:12:"field_note_f";s:250:"Pour les produits à ingrédients multiples contenant des protéase de A. niger et de A. oryzae, l’activité protéolytique maximale provenant de ces deux sources ne doit pas dépasser 680000 FCC HUT, par jour et/ou 6800  FCC SAP, par jour (FCC 8).";s:16:"field_legacy_nid";s:6:"100687";s:14:"field_workflow";s:9:"Published";s:5:"title";s:224:"FUNPRO3_For multi-ingredient products containing protease from A. niger and protease from A. oryzae, the maximum proteolytic activity from both sources cannot exceed 680000 FCC HUT per day and/or 6800 FCCSAP per day (FCC 8).";s:3:"nid";s:6:"215344";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215345;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"FUNPRO4";s:12:"field_note_e";s:148:"Enzymatic activity can be either in FCC hemoglobin units on the tyrosine basis per day  and/or  in FCC spectrophometric acid protease units per day.";s:12:"field_note_f";s:191:"L'activiité enzymatique peut être soit en unités d'hémoglobine basées sur la tyrosine, du FCC, par jour  et/ou  soit en unités spectrophotométrique d'acide protéase, du FCC, par jour.";s:16:"field_legacy_nid";s:6:"100688";s:14:"field_workflow";s:9:"Published";s:5:"title";s:156:"FUNPRO4_Enzymatic activity can be either in FCC hemoglobin units on the tyrosine basis per day  and/or  in FCC spectrophometric acid protease units per day.";s:3:"nid";s:6:"215345";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215346;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"GALAC";s:12:"field_note_e";s:189:"One FCC galactosidase activity unit (GalU) is defined as the quantity of the enzyme that will liberate p-nitrophenol at the rate of 1 micromol/min under the conditions of the assay (FCC 8).";s:12:"field_note_f";s:186:"Une unité FCC de galactosidase (GalU)  est définie comme étant la quantité d’enzymes qui libère le p-nitrophénol à un taux de 1 micromol/min dans les conditions du test (FCC 8).";s:16:"field_legacy_nid";s:6:"100689";s:14:"field_workflow";s:9:"Published";s:5:"title";s:195:"GALAC_One FCC galactosidase activity unit (GalU) is defined as the quantity of the enzyme that will liberate p-nitrophenol at the rate of 1 micromol/min under the conditions of the assay (FCC 8).";s:3:"nid";s:6:"215346";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215347;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"LIPA";s:12:"field_note_e";s:160:"One FCC lipase unit (LU) is defined as the quantity of enzyme that will liberate 1 micromol of butyric acid per minute under the conditions of the test (FCC 8).";s:12:"field_note_f";s:167:"L’unité de lipase (LU) est définie comme étant la quantité d’enzymes qui libère 1 micromol d’acide butyrique par minute dans les conditions du test (FCC 8).";s:16:"field_legacy_nid";s:6:"100690";s:14:"field_workflow";s:9:"Published";s:5:"title";s:165:"LIPA_One FCC lipase unit (LU) is defined as the quantity of enzyme that will liberate 1 micromol of butyric acid per minute under the conditions of the test (FCC 8).";s:3:"nid";s:6:"215347";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215348;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"PAPA1";s:12:"field_note_e";s:167:"One papain unit (PU) is defined as that quantity of enzyme that liberates the equivalent of 1 microgram of tyrosine per hour under the conditions of the assay (FCC 8).";s:12:"field_note_f";s:182:"Une unité de papaïne (PU) est définie comme étant la quantité d’enzymes qui libère l’équivalent de 1 microgramme de tyrosine par heure dans les conditions du test (FCC 8).";s:16:"field_legacy_nid";s:6:"100691";s:14:"field_workflow";s:9:"Published";s:5:"title";s:173:"PAPA1_One papain unit (PU) is defined as that quantity of enzyme that liberates the equivalent of 1 microgram of tyrosine per hour under the conditions of the assay (FCC 8).";s:3:"nid";s:6:"215348";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215349;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"PAPA2";s:12:"field_note_e";s:99:"One FCC papain unit is approximately equivalent to one USP papain unit (1 FCC PU approx. 1 USP PU).";s:12:"field_note_f";s:136:"Une unité FCC de papaïne est approximativement équivalente à une unité USP de papaïne (1 FCC PU approx. 1 unité USP de papaïne).";s:16:"field_legacy_nid";s:6:"100692";s:14:"field_workflow";s:9:"Published";s:5:"title";s:105:"PAPA2_One FCC papain unit is approximately equivalent to one USP papain unit (1 FCC PU approx. 1 USP PU).";s:3:"nid";s:6:"215349";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215350;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:5:"PAPA3";s:12:"field_note_e";s:204:"For multi-ingredient products containing both papain and bromelain (fruit and/or stem), the combined proteolytic activity should not exceed the maximum proteolytic activity of  130 000 000 FCC PU per day.";s:12:"field_note_f";s:246:"Pour les produits à ingrédients multiples qui contiennent de la papaïne et de la bromelaïne (fruit et/ou tige), l’activité protéolytique combinée ne doit pas dépasser l’activité protéolytique maximale de 130 000 000 FCC PU par jour.";s:16:"field_legacy_nid";s:6:"100693";s:14:"field_workflow";s:9:"Published";s:5:"title";s:210:"PAPA3_For multi-ingredient products containing both papain and bromelain (fruit and/or stem), the combined proteolytic activity should not exceed the maximum proteolytic activity of  130 000 000 FCC PU per day.";s:3:"nid";s:6:"215350";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215351;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"TRYP";s:12:"field_note_e";s:127:"One USP trypsin unit is the activity causing a change in the absorbance of 0.003/min under the conditions of the assay (FCC 8).";s:12:"field_note_f";s:160:"L’unité USP de trypsine est définie comme étant l’activité qui cause un changement dans l’absorbance de 0.003/min dans les conditions du test (FCC 8).";s:16:"field_legacy_nid";s:6:"100694";s:14:"field_workflow";s:9:"Published";s:5:"title";s:132:"TRYP_One USP trypsin unit is the activity causing a change in the absorbance of 0.003/min under the conditions of the assay (FCC 8).";s:3:"nid";s:6:"215351";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215352;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:6:"PANENZ";s:12:"field_note_e";s:485:"Pharmacopoeial units other than USP may be represented on the label as additional information. The following approximate conversion factors can be used to convert the activities of pancreatic enzymes into USP units (Scharpé et al. 1997):  (i) For protease: 1 Ph. Eur. Unit = 1 BP Unit = 1 FIP Unit approx. 62.5 USP Units, (ii) For amylase:  1 Ph. Eur. Unit = 1 BP Unit = 1 FIP Unit approx. 4.15 USP Units, (iii) For lipase:  1 Ph. Eur. Unit = 1 BP Unit = 1 FIP Unit approx. 1 USP Unit";s:12:"field_note_f";s:572:"En plus des unités USP, d’autres unités officinales peuvent apparaître sur l’étiquette comme information supplémentaire. Les facteurs de conversion suivants peuvent être utilisés pour convertir les activités des enzymes pancréatiques en unités USP (Scharpé et al. 1997) :  (i) Pour les protéases : 1 unité Ph.Eur. = 1 unité BP = 1 unité FIP approx. 62.5 unités USP, (ii) Pour l’amylase : 1 unité Ph.Eur. = 1 unité BP = 1 unité FIP approx. 4.15 unités USP, (iii) Pour la lipase :  1 unité Ph.Eur. = 1 unité BP = 1 unité FIP approx. 1 unité USP";s:16:"field_legacy_nid";s:6:"100695";s:14:"field_workflow";s:9:"Published";s:5:"title";s:253:"PANENZ_Pharmacopoeial units other than USP may be represented on the label as additional information. The following approximate conversion factors can be used to convert the activities of pancreatic enzymes into USP units (Scharpé et al. 1997):  (i)...";s:3:"nid";s:6:"215352";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215353;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:7:"PANENZ2";s:12:"field_note_e";s:108:"Dose unit information must include the quantities of both the enzyme preparation and its enzymatic activity.";s:12:"field_note_f";s:117:"L'information sur la dose doit inclure la quantité de la préparation d'enzymes ainsi que son activité enzymatique.";s:16:"field_legacy_nid";s:6:"100696";s:14:"field_workflow";s:9:"Published";s:5:"title";s:116:"PANENZ2_Dose unit information must include the quantities of both the enzyme preparation and its enzymatic activity.";s:3:"nid";s:6:"215353";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215354;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"LAC1";s:12:"field_note_e";s:153:"One lactase unit (ALU) is defined as that quantity of enzyme that will liberate o-nitrophenol at a rate of 1 µmol/min under the conditions of the assay.";s:12:"field_note_f";s:172:"Une unité de lactase (ALU) est définie comme étant la quantité de l'enzyme qui libérera du o-nitrophenol à un taux de 1 µmol/min dans les conditions du test (FCC 8).";s:16:"field_legacy_nid";s:6:"100697";s:14:"field_workflow";s:9:"Published";s:5:"title";s:158:"LAC1_One lactase unit (ALU) is defined as that quantity of enzyme that will liberate o-nitrophenol at a rate of 1 µmol/min under the conditions of the assay.";s:3:"nid";s:6:"215354";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215355;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"REIS";s:12:"field_note_e";s:172:"Refer to Appendix 1 for examples of dosage preparations and directions for use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:12:"field_note_f";s:198:"Se référer à l’annexe 1 pour des exemples de préparations posologiques, de fréquences et de modes d’emploi selon les références citées. L’annexe 1 a pour objet de guider l’industrie.";s:16:"field_legacy_nid";s:6:"100698";s:14:"field_workflow";s:9:"Published";s:5:"title";s:177:"REIS_Refer to Appendix 1 for examples of dosage preparations and directions for use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:3:"nid";s:6:"215355";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215356;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:3:"CIN";s:12:"field_note_e";s:172:"Refer to Appendix 1 for examples of dosage preparations and directions for use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:12:"field_note_f";s:198:"Se référer à l’annexe 1 pour des exemples de préparations posologiques, de fréquences et de modes d’emploi selon les références citées. L’annexe 1 a pour objet de guider l’industrie.";s:16:"field_legacy_nid";s:6:"100699";s:14:"field_workflow";s:9:"Published";s:5:"title";s:176:"CIN_Refer to Appendix 1 for examples of dosage preparations and directions for use, according to cited references. The purpose of Appendix 1 is to provide guidance to industry.";s:3:"nid";s:6:"215356";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}i:215357;a:10:{s:4:"body";s:0:"";s:10:"field_code";s:4:"MRSH";s:12:"field_note_e";s:275:"Cold infusion/macerate for the dosage forms “powder” or “loose/dried herb/herbal tea”:
Add 2-5 g powder/dried herb/herbal tea to 150 ml cold water and let steep for 30 minutes. Stir frequently. Strain and warm (if desired) before drinking (Blumenthal 2000; BHC 1996).";s:12:"field_note_f";s:365:"Infusion à froid / macérat de la forme posologique « poudre » ou'« herbes en vrac/séchées/ tisane » :
Ajouter 2 à 5 g de poudre/d’ herbes en vrac/séchées/ de tisane à 150 mld'eau froide et laisser infuser pendant 30 minutes. Remuer fréquemment. Égoutter et réchauffer (au goût) avant de boire (Barnes 2007; Mills et Bone 2005; BHC 1992; BPH 1983).";s:16:"field_legacy_nid";s:6:"100700";s:14:"field_workflow";s:9:"Published";s:5:"title";s:102:"MRSH_Cold infusion/macerate for the dosage forms “powder” or “loose/dried herb/herbal tea”:...";s:3:"nid";s:6:"215357";s:7:"changed";s:10:"2013-10-16";s:14:"workflow_state";s:9:"Published";}}